Official Title:  A Single -Center, Multiple- Dose, Randomized, Double- Blind, Placebo-
Controlled, Positive-C ontrolled, Crossover Study to Investigate the 
Effect of Balovapton on the Qtc Interval in Healthy Subjects 
Study ID: [REMOVED] 
Document  Date : Protocol  Version 3: 23-April- 2019 
FINA L PROTOCOL A PPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contain ed in this document, especially 
any unpublished data, is the property of F.Hoffmann -La [COMPANY_002] Ltd (or u nder its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff , and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to w hom the drug may  be administered.
Balovaptan —F. Hoffmann -La [COMPANY_002] Ltd
Protocol WP40734 , Version 3.0 PROTOCOL
TITLE: A SINGLE -CENTER, MUL TIPLE -DOSE, 
RANDOMIZED, DOUBLE -BLIND, PLA CEBO -
CONTROLLED, POSITIVE -CONTROLLED, CROSS-
OVER STUDY TO INVEST IGATE THE EFFECT OF 
BALOVAPTAN ON THE QT C INTERVA L IN 
HEA LTHY SUBJECTS
PROTOCOL NUMBER: WP40734
VERSION NUMBER: V3.[ADDRESS_1007972] NUMBER: NA
IND NUMBER: [ADDRESS_1007973]: Balovaptan (RO5285119)
MEDICA L MONITOR: , MD
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: See electronic date stamp below
 
23-Apr-2019 06:19:00
Title
Approver's Name
[CONTACT_26862] (UTC)

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
2/Protocol WP40734 , Version 3.0Document Date of Issue Approver(s) Summary of Change s
Original 
ProtocolOct-23-2018 Not Applicable
Protocol v2.0 
Amendment 1
and 
Administrative 
letter 1 ,Nov-
13-2018See date 
stamp on the 
cover page.Change sin wording regarding 
intensive PK sampling for 
balovaptan and moxifloxacin outlined in Administrative 
letter from Nov -13-2018 incorporated.
Reference to balovaptan sampling on Day [ADDRESS_1007974] been 
removed .
The 1.[ADDRESS_1007975] -dose. This information has 
been updated in Appendi cesand protocol text .
Section 4. 4 has been edited to clarify that concomitant 
therapy should be captured from 30days prior to initiation 
of study drug .
The text in Section 4.4.2 regarding prohibited therapi[INVESTIGATOR_737733].
Text in Section 4.4.4 has been edited to remove the 
statement “Subjects should have fasted for at least 8 hours 
prior to the screening visit, each admission to the CRU, 
and the Follow up visit ”
as it redundant with the collection 
description in Section [IP_ADDRESS] .
Text has been added to Section 4.[ADDRESS_1007976]’s fluid intake.
In Section 4.5.3 Physical Examinations the phrase “Any 
abnormality identified ” has been updated to read “Any 
clinically significant abnormalities identifie d”
Instructions for collection and handling of PK samples in 
Section [IP_ADDRESS] has been updated. 
Text reading safety ECG readings in Section [IP_ADDRESS] has 
been edited for clarity.
Section 4.6.1 has been edited for clarity regarding 
assessments for subjects who withdraw or are terminated 
from the study early.
Text regarding ECG extraction on consecutive days has 
been edited throughout the document to clarify that when 
a reading is taken on consecutive days (Day 2 and 
Day 15) the 24 h time point can be taken from the 3 pre -
dose Holter extractions .
Text regarding analysis of samples for cardiac biomarkers 
has been edited to indicate that samples will be taken but 
only analy zed for specific subjects on request.
Text in Section 5.3.1 has been modified to make it 
consistent with Section [IP_ADDRESS] and Appe ndix 2 clarifying 
that only SAE’s will be recorded prior to study drug 
administration.
Section 6.7.2 has been edited to make text consistent with 
ECG extraction time points throughout protocol .
TQT exclusion criteria #3 and #[ADDRESS_1007977] been edited to 
clarify that criteria should be assessed at both Screening 
Balovaptan —F. Hoffmann- La Roch e Ltd
4/Protocol WP40734 , Version 3.0TABLE OF CONTENTS
PROTOCOL ACCEPTANCE FORM .................................................................. 10
PROTOCOL SYNOPSIS .................................................................................... 11
1. BACKGROUND .......................................................................................... 23
1.1 Autism Spectrum Disorder ..................................................... 23
1.2 Pre-Clinical Background on Balovaptan ................................ 23
1.2.1 Previous and Ongoing Clinical Studies .................................. 25
[IP_ADDRESS] Clinical Pharmacology ........................................................... 25
[IP_ADDRESS] Safety .................................................................................... 26
1.3 Study Rationale and Benefit -Risk Assessment ...................... 28
2. OBJECTIVES AND ENDPO INTS ............................................................... 28
3. STUDY DESIGN ......................................................................................... 31
3.1 Description of the Study ......................................................... 31
3.2 End of Study and Length of Study ......................................... 35
3.3 Rationale for Study Design .................................................... 35
3.3.1 Rationale for Balovaptan and Moxifloxacin Dose 
and Schedule ......................................................................... 35
[IP_ADDRESS] Balovaptan ............................................................................. 35
[IP_ADDRESS] Moxifloxacin ........................................................................... 36
3.3.2 Rationale for Study Population .............................................. 36
3.3.3 Rationale for Transthoracic Doppler-
Echocardiogram and Ambulatory Blood Pressure 
Monitoring .............................................................................. 37
4. MATERIALS AND METHOD S.................................................................... 37
4.1 Subjects ................................................................................. 37
4.1.1 Inclusion Criteria .................................................................... 37
4.1.2 Exclusion Criteria ................................................................... 38
4.2 Method of Treatment Assignment and Blinding ..................... 41
4.2.1 Treatment Assignment ........................................................... 41
4.2.2 Blinding .................................................................................. 42
Balovaptan —F. Hoffmann- La Roch e Ltd
5/Protocol WP40734 , Version 3.04.3 Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 42
4.3.1 Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 43
[IP_ADDRESS] Balovaptan and Placebo ........................................................ 43
[IP_ADDRESS] Moxifloxacin Active Control and Placebo ............................... 43
4.3.2 Study Treatment Dosage, Administration, and 
Com pliance ............................................................................ 43
[IP_ADDRESS] Balovaptan and Placebo ........................................................ 43
[IP_ADDRESS] Moxifloxacin (Active Co ntrol) and Placebo ............................ [ADDRESS_1007978] Accountability ................... 44
4.4 Concomitant Therapy, Prohibited Food, and 
Additional Restrictions ........................................................... 45
4.4.1 Permitted Therapy ................................................................ .45
4.4.2 Prohibited Therapy ................................................................ 45
4.4.3 Prohibited Food ..................................................................... 46
4.4.4 Additional Restrictions/Considerations .................................. 46
[IP_ADDRESS] Herbal Therapi[INVESTIGATOR_014] ................................................................... 47
4.5 Study Assessments ............................................................... 47
4.5.1 Informed Consent Forms and Screening Log ........................ 47
4.5.2 Medical History, Concomitant Medication, and 
Demographic Data ................................................................ .47
4.5.3 Physical Examinations ........................................................... 47
4.5.4 Vital Signs .............................................................................. 48
4.5.5 Laboratory, Genotypi[INVESTIGATOR_007], and Pharmacokinetic 
Samples ................................................................................. 48
[IP_ADDRESS] Laboratory Samples .............................................................. 48
[IP_ADDRESS] Pharmacokinetic Samples ..................................................... 49
[IP_ADDRESS] Optional Samples for Genetic Analyses ................................ 49
4.5.6 Electrocardiograms ................................................................ 50
[IP_ADDRESS] 12-lead Safety Electrocardiograms ........................................ 50
[IP_ADDRESS] Cardiodynamic ECG Evaluation ............................................ 51
4.5.7 Transthoracic-Doppler Echocardiography ............................. 53
4.5.8 Ambulatory Blood Pressure Monitoring ................................ .54
4.5.9 Columbia -Suicide Severity Rating Scale ............................... 55
Balovaptan —F. Hoffmann- La Roch e Ltd
7/Protocol WP40734 , Version [IP_ADDRESS] Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor) .................................................... 65
5.3 Methods and Tim ing for Capturing and 
Assessing Safety Parameters ................................................ 66
5.3.1 Adverse Event Reporting Period ........................................... 66
5.3.2 Eliciting Adverse Event Information ....................................... 67
5.3.3 Assessment of Severity of Adverse Events ........................... 67
5.3.4 Assessment of Causality of Adverse Events ......................... 67
5.3.5 Procedures for Recording Adverse Events ............................ 68
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ................................ .68
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................... 69
[IP_ADDRESS] Persistent or Rec urrent Adverse Events ................................ 69
[IP_ADDRESS] Abnormal Laboratory Values ................................................. 69
[IP_ADDRESS] Abnormal Vital Sign Values ................................................... 70
[IP_ADDRESS] Abnormal Liver Function Tests .............................................. 71
[IP_ADDRESS] Deaths ................................................................................... 71
[IP_ADDRESS] Preexisting Medical Conditions .............................................. 71
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] .......................... [ADDRESS_1007979] ..................... 73
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................... 73
[IP_ADDRESS] Events That Occur after Study Drug Initiation ........................ 74
5.4.3 Reporting Requirements for Pregnancies .............................. 74
[IP_ADDRESS] Pregnancies in Female Subjects ........................................... 74
[IP_ADDRESS] Pregnancies in Female Partners of Male 
Subjects ................................................................................. 74
[IP_ADDRESS] Abortions ............................................................................... 75
[IP_ADDRESS] Congenital Anomalies/Birth Defects ...................................... 75
5.4.4 Reporting Requirements for Cases of Accidental 
Overdose or Medication Error ................................................ 75
5.5 Follow -Up of Subjects after Adverse Events .......................... 76
Balovaptan —F. Hoffmann- La Roch e Ltd
8/Protocol WP40734 , Version [IP_ADDRESS] Investigator Follow -Up........................................................... [ADDRESS_1007980] of Study ............................................ 78
6.3 Summaries of Demographic and Baseline 
Characteristics ....................................................................... 78
6.4 Efficacy Anal yses .................................................................. 78
6.5 Safety Analyses ..................................................................... 78
6.6 Pharmacokinetic Analyses ..................................................... 79
6.7 Cardiodynamic ECG Evalutaion ............................................ 80
6.7.1 Analysis Populations ............................................................. 80
6.7.2 Baseline ................................................................................. 81
6.7.3 By-Time Point Analysis .......................................................... 81
6.7.4 Secondary Analysis ............................................................... 82
6.7.5 Assay Sensitivity .................................................................... 82
6.7.6 Categorical Analyses ............................................................. 82
6.7.7 Concentration -QTc Analysis (Secondary Analysis)
.............................................................................................. 83
6.7.8 Investigation of Hysteresis ..................................................... 84
6.8 TT-Doppler Echocardiogram ................................................. 85
6.9 Blood Pressure and Heart Rate Monitoring ........................... 85
7. DATA COLLECTION AND MANAGEMENT ............................................... 86
7.1 Data Quality Assurance ......................................................... 86
7.2 Electronic Case Report Forms ............................................... 87
7.3 Source Data Documentation .................................................. 87
7.4 Use of Computerized Systems .............................................. 87
7.5 Retention of Records ............................................................. 88
8. ETHICAL CONSIDERATIO NS.................................................................... 88
Balovaptan —F. Hoffmann- La Roch e Ltd
9/Protocol WP40734 , Version 3.08.[ADDRESS_1007981] Morphology Categories (Assessed Manually) ................ [ADDRESS_1007982] OF A PPENDICES
Appendix 1 Schedule of Activities .................................................................. 95
Appendix 2 Schedule of Pharmacokinetic, Vital Signs, and ECG .................. 97
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
10/Protocol WP40734 , Version 3.0PROTOCOL A CCEPTA NCE FORM
TITLE: A SINGLE -CENTER, MULTI PLE-DOSE, 
RANDOMIZED, DOUBLE -BLIND, PLA CEBO -
CONTROLLED, POSITIVE -CONTROLLED ,CROSS -
OVER STUDY TO INVEST IGATE THE EFFECT OF 
BALOVAPTAN ON THE QTC INTERVA L IN 
HEA LTHY SUBJECTS
PROTOCOL NUMBER: WP40734
VERSION NUMBER: v3.[ADDRESS_1007983] NUMBER: NA
IND NUMBER: [ADDRESS_1007984]: Balovaptan (RO5285119)
MEDICA L MONITOR: , MD
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator’s Name (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy of 
the signed form by [CONTACT_371422].
[COMPANY_002] Products Limited
6 Falcon W ay, Shire Park
Welwyn Garden City,
AL7 1T W, [LOCATION_008]

Balovaptan —F. Hoffmann- La Roch e Ltd
11/Protocol WP40734 , Version 3.0PROTOCOL SYNOPSIS
TITLE: A SINGLE -CENTER, MUL TIPLE -DOSE, RA NDOMIZ ED, DOUBLE -
BLIND, PLACEBO -CONTROLLED, POSITIVE -CONTROLLED,
CROSS -OVER STUDY TO INVESTIGA TE THE EFFE CT OF 
BALOVA PTAN ON THE QT C INTERVA L IN HEA LTHY SUBJECTS
PROTOCOL NUMBER: WP40734
VERSION NUMBER: v3.[ADDRESS_1007985] NUMBER: NA
IND NUMBER: [ADDRESS_1007986]: Balovaptan (RO5285119 )
PHASE: Phase 1
INDIC ATION: Not applicable
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives and Endpoints
This study will investigate the effect of balovaptan (RO5285119) on cardiac repolarization by 
[CONTACT_737758] -therapeutic doses.
Primary Objective Corresponding Endpoint
1.To investigate the effect of balovaptan 
50 mg QD on the QTcF interval after 14 
days of dosing.1.Placebo -corrected, change -from-baseline QTcF
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day [ADDRESS_1007987] of a single dose 
of balovaptan 50 mg on the QTcF 
interval at Day 1.1.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day [ADDRESS_1007988] of balovaptan 
10 mg QD on the QTcF interval at Day 1 
and Day 14.2.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day 1 and Day 14.
Balovaptan —F. Hoffmann- La Roch e Ltd
12/Protocol WP40734 , Version 3.03.To investigate the effect of balovaptan
on the following ECG parameters: PR, 
RR, QRS, QT, T -wave and U -wave 
morphology.3.Placebo -corrected, change -from-baseline heart 
rate(HR) , PR and QRS interval ( HR, PR 
and QRS) measured on 12-lead ECGs 
extracted from continuous recordings at the 
specified time points on Day 1 and Day 14 .
Categorical outliers for QTcF, HR, PR, and 
QRS .
Frequenc y of treatment emergent changes of 
T-wave m orphology and U -wave presence.
4.To investigate the pharmacokinetics of 
balovaptan, M2 (as appropriate) and 
M3.4.Pharmacokinetic parameters estimation such as 
Tmax, Cmax, and AUC0 -24h for plasma 
concentrations of balovaptan, M2 (as 
appropriate) andM3.Other pharmacokinetic 
parameters may  also be added.
5.To investigate the pharmacokinetics of 
moxifloxacin .5.Pharmaco kinetic parameters estimation such as 
Tmax, Cmax, and AUC0 -24h for plasma 
concentrations of moxifloxacin. Other 
pharmacokinetic parameters may  also be added.
6.To investigate the relationship between 
plasma concentrations of balovaptan, 
M2(as appropriate) , M3 and QTcF 
interval length .6.Pharmacokinetic -pharmacodynamic model of 
balovaptan, M2 (as appropriate) andM3 
concentrations vs. QTcF changes .
7.To investigate the relationship between 
plasma concentrations of moxifloxacin 
and QTcF interval length (if warranted) .7.Pharmacokinetic -pharmacodynamic model of 
moxifloxacin concentrations vs. QTcF changes (if 
warranted) .
8.To investigate the ECG assay sensitivity 
to detect a change in the QTcF interval, 
using moxifloxacin 400 mg as an active 
control8.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day 2 and Day 15 .
9.To investigate the safety and tolerability 
of balovaptan and moxifloxacin at the 
dosing regimens scheduled.9.Safety assessments: adverse events , physical 
examination , vital signs , laboratory tests , 
C-SSRS and HR monitoring .
Exploratory Objective s Corresponding Endpoints
1.To investigate any effect of balovaptan
at 50 mg QD and 10 mg QD doses on 
pulm onary blood pressure as asse ssed 
by [CONTACT_737759] -doppler 
echocardiography .1.TT-Doppler echocardiography: pulmo nary arter y 
acceleration time (PAAT), right ventricular 
outflow tract -velocity time integral (RVOT -VTI) 
and derived mean pulmonary arterial pressure as 
change to baseline relative to placebo treatment.
Balovaptan —F. Hoffmann- La Roch e Ltd
13/Protocol WP40734 , Version 3.02.To investigate any effect of 50 mg qd 
and 10 mg qd on right and left heart as 
assessed by [INVESTIGATOR_118059] -Doppler echo.2.TT-Doppler -echocardiography: LVEF and 
additional secondary TT -Doppler -
echocardiography parameters of left and right 
heart, as described in Section 4.5.7 (also for 
objective 1)
3.To investigate the effect 10 mg and 50 
mg QD balovaptan on blood pressure 
and heart rate as measured by [CONTACT_737760]-ECG and ABPM .3.Ambulator y blood pressure monitoring (ABPM): 
mean diastolic and systolic blood pressure 
(daytime and nighttime mean).
Heart rate will also be analyzed as 
derived from Holter E CG.
-Heart rate as derived from ABPM 
and/or Holter ECG may  be 
explored against fluctuations in 
blood pressure measured by 
[CONTACT_44117] (if warranted).
4.To investigate whether genetic variants 
in genes are associated with natural or 
potential drug induced neutropenia ;with 
differences in pharmacokinetics of 
balovaptan, M2 or M3, or with any 
potential effect of balovaptan on ECG 
parameters.5.The genetic variants in genes that are associated 
with natural or potential drug induced 
neutropenia; genetic variants in genes that are 
associated with pharmacogenetics of 
metabolizing enzy mes, transferases, 
transporters, etc, (eg,CYP3A4 and P -
glycoprotein); genetic variants in genes that may  
be associated with a potential effect of 
balovaptan on ECG parameters.
Study Design
This will be a single -center, multiple -dose, randomized, double -blind, placebo -controlled, positive -
controlled, twelve sequence, [ADDRESS_1007989] of balovaptan on 
the QTc interval in healthy subjects .
Screening
Screening will be conducted up to 28 and 3 days (inclusive) before each subject’s first 
dosing day (Day  1 of Treatment Period 1). 
In-Clinic Confinement
Day -2
Subjects will be confined to the CRU starting on Day -2 until the morning of Day 16 during 
each Treatment Period. Subjects are entered into CRU on Day - 2 so that subjects are 
rested and prepared for the baseline ABPM and baseline TT -Doppler echocardiogram on 
Day -1.  Eligibility assessments will be performed on Day -2 as outlined in t he Schedule of 
Activities (SoA ),Appendix 1.
Day -1
On Day -1 of each T reatment Period, ABPM and TT -Doppler echocardiogram assessments 
will be performed.  These results will serve as the baseline for the subjects.  On days when 
TT-Doppler echocardiogram and ABPM assessments are performed subjects will be given 
low salt standardized meals.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
14/Protocol WP40734 , Version 3.0Randomization (Day -1)
At the start of the study in Treatment Period 1, at the end of the day of Day-1, subjects will 
be randomized to one of the 12 treatment sequences comprised of the 4 treatments 
described:
Treatments
Treatment A  (balovaptan therapeutic dose)
Days 1 -14: A single once daily oral dose of 10 mg (1 × 10 mg tablet) of balovaptan and 
4tablets of matching placebo for balovaptan for 14 days.
Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Treatment B (balovaptan supra -therapeutic dose)
Days 1 -14: A single once daily oral dose of 50 mg (5 x 10 mg tablets) of balovaptan for 
14days.
Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Treatment C (active control [400 mg moxifloxacin] on Day 2)
Days 1 -14: A single once daily oral dose of 5 tablets of matching placebo for balovaptan 
for 14 days.
Day 2: A single oral dose of 400 mg moxifloxacin capsule
Day 15: A single oral dose of a matching placebo capsule for moxifloxacin 
Treatment D (active control [400 mg moxifloxacin] on Day 15)
Days 1 -14: A single once daily o ral dose of 5 tablets of matching placebo for balovaptan 
for 14 days.
Day 2: A single oral dose of a matching placebo capsule for moxifloxacin
Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Treatment Sequences
1.A, B, C
2.A, C, B
3.B, A, C
4.B, C, A
5.C, A, B
6.C, B, A
7.A, B, D
8.A, D, B
9.B, A, D
10.B, D, A
11.D, A, B
12.D, B, A
Dosing (Days 1 -15)
Each Treatment Period will involve 15 days of dosing (Day 1 –Day15).  Subjects must fast 
for at least 8 hours prior to and 4 hours after dosing on study days when 24 -hour Holter ECG 
assessments will be performed (study  Days1, 2, 14 and 15).  Dosing on study days with 
24-hour Holter ECG assessment should be at approximately the same time of day ± 1h.
Prior to dosing on Day 1 subjects will undergo pre -dose assessments a s outlined in the SoA 
(Appendix 1).  Following pre-dose assessments subjects will receive a single dose of study 
medication preceded by a ≥[ADDRESS_1007990]. If subjects require more liquid 
to take all study drugs, additional water may be provided in aliquots of 50 mL .  If additional 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
15/Protocol WP40734 , Version 3.0water is provided the amount should be captured. Water provided for study drug 
administration will be identical on all dosing days.  Identical fasting procedures from Day  1 
will be followed on study Days 2, 14 and 15.  No fasting will be required on other dosing 
days.  Subjects will receive standardized low salt meals on study days when 24- hour Holter 
ECGs (Days 1, 2, 14 and 15) , ABPM (Day s -1and 12 )orTT-Doppler echocardiogram
(Days -1and 13) assessments will be performed . Meals will be given at approximately the 
same tim e on each of these study  days.
Days 1 and 2 :24-hour Holter ECG A ssessments
On study Days 1 and 2 of each Treatm ent Period, 24 -hour ECG assessments will be 
performed.  Subjects will be administered study drug following a ≥ [ADDRESS_1007991]- dose 
assessments as outlined in the SoA ( Appendix 1).
Day [ADDRESS_1007992] -dose assessments as 
outlined in the SoA ( Appendix 1).
Day [ADDRESS_1007993]-dose assessments as outlined in the SoA ( Appendix 1).
Days 14 and 15 : 24-hour Holter ECG A ssessments
On study Days 14 and 15 of each study T reatmen t Period ,24-hour ECG assessments will 
be performed. Subjects will be administered study drug following a ≥[ADDRESS_1007994]- dose assessments as outlined 
in the SoA ( Appendix 1).
Day [ADDRESS_1007995] the clinical research unit ( CRU ) on the morning of Day 16 after final 
assessments as described in the SoA ( Appendix 1).
Washout Period:
Following each Treatment Period subjects will undergo a washout period lasting a minimum 
of [ADDRESS_1007996] dose of study drug.
Follow -up:
Subjects will return to the unit for a follow -up visit between [ADDRESS_1007997] 1/3 male subjects by 
[CONTACT_151073] a minimum of 40% of enrolled population are male.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
16/Protocol WP40734 , Version 3.0Inclusion Criteria
Subjects must meet the following criteria for study entry:
1.Healthy male or female volunteers aged 18 to 60 years inclusive, at screening.  Healthy 
status is defined by [CONTACT_317347] a 
detailed medical and surgical history, a complete physical examination including vital 
signs, 12 -lead ECG, hematology, blood chemistry , urinaly sis, and serology.
2.Body Mass Index (BMI) between 18 and 32 kg/m2inclusive, at Screening.
3.For women of childbearing potential: agreement to use at least [ADDRESS_1007998] dose of study dru g. 
a.A woman is considered to be of childbearing potential if she is postmenarcheal, 
has not reached a postmenopausal state ( >12 continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovari es and/or uterus). 
b.The following are acceptable contraceptive methods: abstinence from 
heterosexual activity; bilateral tubal ligation; sterilization of male partner; 
hormonal contraceptives; hormone -releasing intrauterine devices; copper 
intrauterine devices; Essure .
c.Barrier methods alone are not considered an acceptable form of contraception 
for this study and if utilized must be supplemented by [CONTACT_737761]. For this study ,barrier contraception methods are 
defined a s:male or female condom with or without spermicide (male and female 
condom must not be used simultaneously); and cap, diaphragm, or sponge with 
spermicide.
4.For men: Vasectomized, agreement to remain abstinent (refrain from heterosexual 
intercourse) or us e of a condom during intercourse. Must also agree to refrain from 
donating sperm, as defined below:
a.With female partners of childbearing potential or pregnant female partners, men 
must remain abstinent or use a condom during the entire study and for [ADDRESS_1007999] refrain 
from donating sperm during this same period.
5.Able to participate, and willing to give written informed consent and to comply with the 
study restrictions.
6.Fluent in English .
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from study entry:
Past Me dical History
1. History of any clinically significant gastrointestinal, renal, hepatic, broncho -pulmonary, 
neurological, psychiatric, cardiovascular, endocrinological, hematological, ly mphatic, 
musculoskeletal, genitourinary, immunological, dermatological or connective tissue or 
allergic disease, metabolic disorder, or cancer.
2. Signs and sy mptoms potentially indicative of peripheral neuropathy .
3. Unexplained orthostatic reaction with syncope within last 6 months.
4. A history of clinically significant hypersensitivity (e .g., to drugs, including moxifloxacin or any 
quinolone antibiotics and balovaptan, and excipi[INVESTIGATOR_840]) or allergic reactions .
5. History of alcohol and/or drug abuse or addiction within the last 2 years before study 
enrollment.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
17/Protocol WP40734 , Version 3.06. Subjects on hormone replacement therapy if post -menopausal status cannot be documented 
from medical histor y.
7. Previous treatments with iron for iron deficienc y anem ia within three months of screening.
8. History of coagulopathies, bleeding disorders, or blood dy scrasias.
9. History of porphyria, active liver disease or permanent or unexplained elevation of serum 
transaminases.
10. In the opi[INVESTIGATOR_737734], any major illness within one month before the 
screening examination or any febrile illness within one week prior to Screening and up to first 
study drug administration.
Current Status
1. Clinically relevant deviation from normal in the physical exami nation including vital signs .
2. Positive result on human immunodeficiency virus (HIV) 1, HIV 2, hepatitis C virus (HCV) 
antibody, or hepatitis B virus surface antigen (HBsAg) .
3. Clinically significant abnormalities in laboratory test results (including complet e blood count, 
chemistry  panel, and urinalysis). In the case of uncertain or questionable results, tests 
performed during S creening may  be repeated on Day -[ADDRESS_1008000] at screening or prior to Day 1 of any Treatment Period.
5. Lactating women .
6. Any condition or disease detected during the medical interview / physical examination that 
would render the subject unsuitable for the study, place the subject at undue risk or interfere 
with the ability of the subject to complete the study in the opi[INVESTIGATOR_1649] o f the Investigator or 
designee. 
7. Subjects with CPK values > 2x upper limit of normal (ULN), confirmed by [CONTACT_318278] .
8. Positive urine alcohol test or urine drug test at Screening or Day - 2 of each T reatment Period 
(amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine, opi[INVESTIGATOR_858], methadone, 
metham phetamines, and 3,4 -methylenedioxy methamphetamine [MDMA ]).
9. Subject has been a regular smoker (> 5 cigarettes, > 1 pi[INVESTIGATOR_737735], > 1 cigar per day or 
equivalent as determined by [CONTACT_737762]) within 6months of study enrollment.
10. Coffee (or tea) consumption > 5 cups per day or methylxanthine -containing drinks >1.5 
liter/day or more than 250 g/day of chocolate within [ADDRESS_1008001] dose of study drug. 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
18/Protocol WP40734 , Version 3.011. Alcohol consumption of > [ADDRESS_1008002] or donated in excess of ~450 mL blood in the 3 months prior to 
Day1 ofTreatment Period 1 .
13. Subjects under judicial supervision, guardianship, or curatorship.
14. Dietary restrictions that would prohibit the consumption of standardized meals.
15. Poor venous access for blood sampling.
Concomitant Medication
1.Taken greater than 2 g/day paracetamol within 48 hours of study drug administration or 
greater than 4 g/day  paracetamol within [ADDRESS_1008003] dose administration are excluded, unless in the opi[INVESTIGATOR_689] (or 
designee) the medication will not interfere with the study procedures or co mpromise safety. 
6.Any slow release medicinal formulations considered to still be active within 4 weeks (or within 
5times the elimination half -life of the medication, whichever is longer) prior to the first study 
drug administration are prohibited, unless in the opi[INVESTIGATOR_737736].
7.Taking any inhibitor of CYP3A taken within 4 weeks (or within 5 half-lives, whichever is longer) 
prior to study drug administration or taking any inducer of CYP3A within [ADDRESS_1008004] unsuitable to participate in this 
study.
3. Subjects experiencing fainting or pre- syncopal events durin g orthostatic challenge testing, 
performed according to site SOP, at Screening or Day-2 of Treatment Period 1.
4. Subjects with Screening or Treatment Period 1(Day -2) baseline mean QT interval corrected 
using Fridericia’s formula (QTcF) > 450msor <300ms(using the same upper QTcF limit in 
both males and females) or > 30msdifference between the highest and the lowest of the 
triplicate readings.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
19/Protocol WP40734 , Version 3.05. Screening or baseline (Day -2,Treatment Period 1) ECG evidence of atrial fibrillation, atrial 
flutter, seco nd or third -degree AV block, complete right or left bundle branch block, 
Wolff-Parkinson -White-syndrome, or cardiac pacemaker.
6. Screening or baseline ECGs (Day -2 of Treatment Period 1) with QRS and/or T -wave judged 
to be unfavorable for a consistently accurate QT measurement (i .e., neuromuscular artifact 
that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T -wave, 
merged T -and U -waves, prominent U -waves, etc.).
7. Confirmed (based on the average of ≥ 3 consecutive measurements) sy stolic blood pressure 
greater than 139 or less than 90 mmHg, and diastolic blood pressure greater than 89 or less 
than 45mmHg at Screening or Day -2of Treatment Period 1.
8. Confirmed (based on the average of ≥ 3 consecutive measurements) resting HR >100bpm 
or <40bpm atScreening or Day -2 of Treatment Period 1.
9. Notable resting bradycardia (HR < 40bpm) on ECG at Screening or Day -2 of Treatment 
Period 1. Notable resting tachycardia (mean HR > 100bpm) on ECG atScreening or Day-[ADDRESS_1008005] the duration of the study 
from Screening to the end of Follow -up will be a minimum of 122 days or a maximum of 143 days.
Screening: up to 28 days
Dosing periods including washout: 80 –94 day s
oTreatment Period 1: 18 Days (Day -2 –Day16)
oWashout: 13 -20 Day s
oTreatment Period 2: 18 Days (Day -2 –Day16)
oWashout: 13 -20 Day s
oTreatment Period 3: 18 Days (Day -2 –Day16)
Follow up: [ADDRESS_1008006] (Investigational Drug)
Balovaptan 10mg (Therapeutic dose) orally, once -daily for 14 days
Balovaptan 50 mg (Supratherapeutic dose) orally, once -daily for 14 days
Moxifloxacin 400 mg, single , oral dose
Comparator
Placebo controlled
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
20/Protocol WP40734 , Version 3.0Statistical Methods
For cardiodynamic ECG evaluation, the primary  analysis will be based on by -time point analysis 
to evaluate the effect of balovaptan on the placebo -corrected change -from-baseline QTcF 
(ΔΔQTcF) at each post -dosing time point using the Intersection U nion Test. The effect of 
balovaptan on placebo -corrected change -from-baseline in HR, PR, and QRS (ΔΔHR, ΔΔPR, and 
ΔΔQRS) will also be evaluated using the Intersection Union Test. In addition, the relationship 
between plasma concentrations of balovaptan a nd its metabolites (M2 [as appropriate] and M3) 
and Δ ∆QTcF will be evaluated using a linear mixed- effects modeling approach. An analy sis of 
categorical outliers will be performed for changes in HR, PR, QRS, QTcF, T -wave m orphology 
and U -wave presence. Assay sensitivity will also be evaluated using by -time point analysis of the 
effect on Δ ∆QTcF of moxifloxacin using a similar model as for the primary analy sis.
Determination of Sample Size :
A sample size of 56 subjects was chosen to obtain 48 evaluable subjects.  Subjects are evaluable 
if ECGs are available for all three periods to allow (1) the derivation of the primary endpoint (i.e., 
change from baseline on Day 14), and (2) the assessment of the effect of moxifloxacin.   
Assuming a 1-sided 5% significance level and a within -subject standard deviation (SD) of 8 ms 
for ΔQTcF and a true mean difference of 3 ms in ΔQTcF between balovaptan and placebo, a 
sample size of 48 evaluable subjects will provide a power of 96.6% to demonstrate tha t the upper 
bound of all the 2 -sided 90% CIs will fall below [ADDRESS_1008007] -dose time points on Day14.  
Sample Size Determination for Assay Sensitivity: Assuming a 1 -sided 5% significance level and a 
within -subject SD of 8 ms for ΔQTcF, a sample s ize of 48 evaluable subjects will provide a power 
of 99% to exclude a mean difference of 5 ms in ΔQTcF between moxifloxacin and placebo groups 
from the lower bound of the 2 -sided 90% CI at least one of the three pre -specified time points.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
21/Protocol WP40734 , Version 3.0LIST OF A BBREVI ATIONS A ND DEFINITION S OF TERMS
Abbreviation Definition
ABPM
                       ambulatory blood pressure monitoring
AE adverse event
ALT alanine transaminase 
ANC absolute neutrophil count
ASD autism spectrum disorder
AST aspartate transaminase
AUC area under the curve
BMI body  mass index
BP blood pressure
BPM beats per minute
Cl confidence interval
Cmax mean maxim um observed plasma concentration
cTnT cardiac t roponin
CNS central nervous system
CPK creatine phosphokinase
CRO contract research organization
CRU clinical research unit
C-SSRS Colum bia-suicide s everity rating s cale (C-SSRS)
CTCAE common terminology criteria for adverse events
Δ change -from-baseline
ΔΔ placebo -corrected change -from-baseline
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
eCRF electronic Case Report Form
EPQT expert precision QT technique
EDC electronic data capture
FDA Food and Drug Administration
FSH follicle- stimulating hormone
GLP good laboratory practice
HBsAg hepatitis B virus surface antigen
HCV hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
hERG human ether -à-go-go related gene

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
22/Protocol WP40734 , Version 3.0HR heart rate
ICH International Council for Harmonisation
IMP investigational medicinal product
IND Investigational New Drug (A pplication)
IRB Institutional Review Board
LDH lactate dehydrogenase
LPLV last patient, last visit
LS least squares
LVEF left ventricular ejection fraction
MAD multiple ascending dose
MDMA 3,4 Methylenedioxy methamphetamine
mEq/L milliequivalents per liter
mmHg millimeters of Mercury
NCI National Cancer Institute 
NT-proBNP N-terminal pro B -type natriuretic peptide
NOAEL no observed adverse effect level
NCI National Cancer Institute
PAAT pulmonary artery acceleration time
P-gp P-Glycoprotein
PK pharmacokinetic
PND postnata l day
PR PR interval of the ECG
PRO patient -reported outcome
QRS QRS interval of the ECG
Q QT interval of the ECG
QTc corrected QT interval
QTcF QTinterval corrected through use of Fridericia’s 
formula
RR RR interval of the ECG
RVOT right ventricular outflow tract
SAD single ascending dose
SAE serious adverse event
SD standard deviation
SE standard error
SOA schedule of activities
Tmax time to reach Cmax
TT trans thoracic
TVI transvalvular impedance
ULN upper limit of normal
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
23/Protocol WP40734 , Version 3.01. BACKGROUND
1.1 AUTISM SPECTRUM DISO RDER
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder
characterized by [CONTACT_737763]: impairments in social interaction and communication
and the presence of repetitive or restricted behaviors, interests, or activities (American
Psychiatric Association, Diagnostic and statistical manual of mental disorders (DSM -5®) 
2013). The Autism and Developmental Disabilities Monitoring Network recently reported, 
based on children records, that the estimated prevalence of ASD in the [LOCATION_002] for 
the year 2010 was 14.7 per 1000 (one in 68) children aged 8 years (Autism and 
Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal 
Investigators, 2014). Core symptoms of ASD affecting domains of socialization, 
communication, and repetitive behavior are usually observed by [ADDRESS_1008008] approach to treat the 
deficits at the core of these disorders.
Balovaptan (RO5285119) is a potent and selective human V1 a receptor antagonist that 
blocks the activation of the V1a G protein -coupled receptor .More detailed information 
around ASD and Balovaptan are presented in the Investigator ’s Brochure.
1.2 PRE-CLINICA L BACKGROUND ON BALOVA PTAN
The in vitro metabolism of balovaptan was studied in hepatic preparations from human, 
rat, dog, minipig, cynomolgus monkey, mouse, and rabbit. In microsomes from all 
species tested, major metabolism pathways were  (formation of M3) 
and  (formation of M1), whereas further secondary metabolites including 
oxidations and desaturations were found at low amounts.
The in vivo pharmacokinetic (PK) studies with balovaptan were conducted in rats, dogs, 
and cynomolgus monkeys. In animals, balovaptan showed a high (r ats) to moderate or 
low (dogs and cynomolgus monkeys) plasma clearance and moderate extravascular
distribution. High to moderate bioavailability, depending on the species, was observed 
after oral application. In human, [ADDRESS_1008009] been shown in vitro to be potentially strong, 
substrate dependent P-glycoprotein (P -gp) inhibitors.  

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
24/Protocol WP40734 , Version 3.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
25/Protocol WP40734 , Version 3.0In vitro cardiovascular safety was assessed in a Good Laboratory Practice (GLP) human 
ether -à-go-go related gene (hERG) assay, and the balovaptan concentration required for 
20% inhibition (IC20) was 4.4 μM, which is orders of magnitude above the free 
concentrations expected to be achieved in man at a 10 mg daily dose. Mild effects on
cardiovascular functions observed in the pi[INVESTIGATOR_737737] a mild 
sustained increase in systolic and mean blood pressu res, paralleled by a left ventricular 
peak systolic increase. An additional mild sustained increase in positive and negative 
dP/dt and a mild transient heart rate (HR) increase was noted. The no observed effect 
level (NOEL) was 10mg/kg. In the GLP safe ty pharmacology studies conducted with 
rats assessing CNS, respi[INVESTIGATOR_696], and renal function, 100 mg/kg was established as the 
NOEL/NOAEL.
Balovaptan was not irritating to the skin or eye in the rabbit, nor did the compound prove 
to be a skin sensitizer.
1.2.1 Previous and On going Clinical Studies
To date, balovaptan has been investigated in 6 completed Phase I studies, including a 
proof -of-mechanism study in healthy volunteers (BP29412). A Phase II study in adult 
male ASD patients has also been completed (BP28 420, also referred to as VANILLA) .
Balovaptan is currently being evaluated in 4 ongoing studies .  Two of these are Phase I 
studies in healthy subjects examining pharmacokinetic CYP3A related drug-drug 
interactions (DDI) , (WP40608 [rifampi[INVESTIGATOR_737738] ] and WP40609 [itraconazole DDI ]).
Balovaptan is also currently being evaluated in a Phase II study (BP30153, also referred 
to as AV1ATION )in pediatric ASD patients anda Phase III study (WN39434 also 
referred to V1aduct )in adult ASD patients.
[IP_ADDRESS] Clinical Pharma cology
Exposure of balovaptan increased in a greater than dose -proportional manner following 
single doses of 0.5 to 76 mg, whereas an approximately linear increase in exposure was 
observed after repeated dosing with 12 to 52 mg once daily (qd) for 14 days.
Balovaptan was rapi[INVESTIGATOR_19627] a median time to maximum observed plasma 
concentration ( Tmax ) between 1 and 4.5 hours after administration of single doses in 
fasted state and between 3 and 4 hours in fed state following multiple dosing. Steady 
state was achieved after approximately 7 days; the mean apparent elimination half -life 
after the last dose (Day 14) was approximately [ADDRESS_1008010] on 
the overall exposure of balovaptan.
In the human mass balance study (Study BP29279), an almost complete absorption of 
the study drug was observed within the first 72 hours following administration.
In plasma, steady state exposure to  M3 was similar to or 
slightly higher than that of balovaptan and ex posure to  M2 
was lower than that of parent. M3 and M2 qualify as major metabolites in plasma.

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
26/Protocol WP40734 , Version 3.0Mean cerebral spi[INVESTIGATOR_872] (CSF) -to-plasma concentration ratios of balovaptan and M3 
following 7days of dosing of 10 and 52 mg qd ba lovaptan were independent of dose. 
The ratio was approximately 12% for balovaptan, which is comparable to the balovaptan 
plasma free fraction (approximately 13%), and 6% for M3, which is lower than the M3 
plasma free fraction (15 to 17%) reflecting M3 bei ng a P -gp substrate .Data regarding 
M2 exposure in CSF is not available at this time.
Hepatic metabolism was found to be the major pathway of elimination with the primary 
route of excretion via urine (approximately 53% of the material recovered, mostly 
composed of metabolites). A further 30% of the administered dose was recovered in 
feces. The majority of excretion occurred within the first 7 days.
There was no clinically/statistically relevant PK interaction with the P -glycoprotein 
substrate risperidone, one of only 2 approved medications for ASD symptoms in the US, 
and fluoxetine, a weak CYP3A4 inhibitor often used to treat associated symptoms of 
ASD. Administration of a single dose of balovaptan 12 mg in combination with 
itraconazole, a strong CYP3A4 inhibitor, resulted in an increase in the exposure of 
balovaptan by 36% for maximum observed plasma concentration (Cmax) and an 
approximately 3.1 -fold increase for area under the concentration curve from time 0 to 
120hours (AUC 0-120h ).
[IP_ADDRESS] Safety
To date, balovaptan has been dosed to 217healthy subjects in 6 completed Phase 1 
studies (Studies BP25694, BP28318, BP28977, BP29279, BP29412, and W P40038).
Additionally, balovaptan was investigated in a completed Phase II study in 148 adult 
male patients with ASD (BP28420, “VANILLA”), about [ADDRESS_1008011] been identified per 
reference safety information (Section 6.4 of the IB). The maximum tolerated dose was 
not reached in either the single ascending dose (SAD) study with single do ses (up to 76 
mg) or the multiple ascending dose (MAD) study with multiple doses (up to 52 mgqd for 
14 days) in healthy subjects. In order to keep an approximately 10 -fold safety margin to
observed in dogs, dose escalation was stopped so as not to exceed a Cmax (mean) of 
810ng/mL in the SAD and MAD studies which compares to Cmax of about 100 and 
500ng/mL after 10 and 50 mg qd dosing.
 
 
 
 
  

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
27/Protocol WP40734 , Version 3.0Balovaptan has also been found to be safe and well tolerated in male patients with ASD 
at doses up to 10 mg/day (highest dose administered) for a period of 12 weeks (Study 
BP28420). No particular safety patterns attributable to the administration of balov aptan 
were identified. A total of 8 serious adverse events ( SAEs )(all but one [rhabdomyolysis] 
considered unrelated to study drug) in 4 patients and 1 adverse event (AE) of special 
interest (neutropenia) were reported in the study. No relevant safety co ncern has 
emerged from the ongoing study in pediatric ASD patients (BP30153) and the recently 
started Phase 3 study in adults ASD patients (W N39434).
 
 
Cardio -vascular SAEs in the clinical program refer to clinically asymptomatic sinus node 
dysfunction / arrhythmia observed in a subject diagnosed with ASD dosed with 1.[ADDRESS_1008012] dosing. ECG monitoring and 
troponin measurement s, which were part of the safety monitoring in this study, had not 
shown abnormalities at any time point. The event was considered “not related” to study 
treatment by [CONTACT_18370] . Of note, the subject had been taking multiple 
co-medications for several years including methylphenidate and aripi[INVESTIGATOR_4253], a 
combination that has been reported to be associated with a higher cardiovascular risk 
potentially .1
ECGs recorded inPhase I studies, including the MAD part of study BP25694 were 
analyzed by [CONTACT_737764] . The preliminary data from 
these studies showed an increase in QTc Fof <5msfor concentrations up to 550ng/mL 
with an upper CI of < 13msat 550 ng/mL. In no ne of the subjects treated with 
balovaptan in the completed Ph
aseI studies were QTcF values observed as 
QTcF >450 ms or increases of QTcF from baseline of > 30 ms, except for a single 
observation but which was < 50ms.
Refer to the Investigator's Brochure for more details on non -clinical and clinical studies.

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
28/Protocol WP40734 , Version 3.01.[ADDRESS_1008013] of balovaptan on cardiac repolarization by [CONTACT_737765] (10mg) 
and supra- therapeutic (50mg) doses.
The study will be performed in healthy subjects who will not receive any health benefit 
from participating in this study. The study is necessary for the further development of
balovaptan and may be of benefit for future subjects .
The doses for the treatment period splanned in this study have been explored in the 
MAD part of study BP25694 and found to be safe and well tolerated. In proof -of-
mechanism study BP29412 a dose of 52mg, once daily ( qd),was administered for 
6days to healthy volunteers (N =35) not revealin g a balovaptan associated safety signal.
QTc analyses based on previous ECG recordings do not indicate relevant ECG changes.
The safety monitoring across all clinical studies has not identified a balovaptan linked 
adverse drug reaction.
Moxifloxacin , a fluoroquinolone antibiotic ,wasapproved for use in the [LOCATION_002] in 
1999 and is currently on the World Health Organization's list of essential medicines .The 
dose of moxifloxacin planned for this study 400mgisthe recommended dosage for 
adults in the package insert. Moxifloxacin has been shown to increase HRandis
associated with mild QT prolongation but only seldom with torsade de pointes .2The 
single dose of moxifloxacin planned for this study will be used as a positive control to 
evaluate the sensitivity of the study to detect increases in QT interval measurements.
The FDA has proposed the use of moxifloxacin in this manner .3
Whileplanned dosing of subjects in this study are expected to be well tolerated ,diligent 
safety monitoring and in- house stays are included in this study during dosing. Subjects 
will be asked to report any events of feeling “not well” to study staff immediately.
In conclusion, any safety risk for the healthy volunteers participating in this study is 
considered minimal.
2. OBJECTIVES A ND ENDPOINT S
This study will investigate the effect of balovaptan (RO5285119) on cardiac 
repolarization by [CONTACT_737766] -thera peutic doses .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
29/Protocol WP40734 , Version 3.0Table [ADDRESS_1008014] of balovaptan 
50 mg qdon the QTcF interval after 
14days of dosing.1.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day14
Secondary Objective s Corresponding Endpoints
1.To investigate the effect of a single dose 
of balovaptan 50 mg on the QTcF 
interval at Day 1.1.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day 1.
2.To investigate the effect of balovaptan 
10 mg qdon the QTcF interval at Day 1 
and Day 14.2.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day [ADDRESS_1008015] of balovaptan 
on the following ECG parameters: PR, 
RR, QRS, QT, T -wave and U -wave 
morphology.3.Placebo -corrected, change -from-baseline heart 
rate, PR and QRS interval ( HR, PR and 
QRS) measured on 12-lead ECGs extracted 
from continuous recordings at the specified time 
points on Day 1 and Day 14.
Categorical outliers for QTcF, HR, PR, and 
QRS .
Frequenc y of treatment emergent changes of 
T-wave m orphology and U -wave presence.
4.To investigate the pharmacokinetics of 
balovaptan, M2 (as appropriate) and 
M3.4.Pharmacokinetic parameters estimation such as 
Tmax, Cmax, and AUC0 -24hfor plasma 
concentrations of balovaptan, M2 (as 
appropriate) andM3. Other pharmacokinetic 
parameters may  also be added.
5.To investigate the pharmacokinetics of 
moxifloxacin .5.Pharmacokinetic parameters estimation such as 
Tmax, Cmax, and AUC0 -24h for plasma 
concentrations of moxifloxacin. Other 
pharmacokinetic parameters may  also be added.
6.To investigate the relationship between 
plasma concentrations of balovaptan, 
M2(as appropriate) , M3 and QTcF 
interval length .6.Pharmacokinetic -pharmacodynamic model of 
balovaptan, M2 (as appropriate) andM3 
concentrations vs. QTcF changes .
Balovaptan —F. Hoffmann- La Roch e Ltd
30/Protocol WP40734 , Version 3.0Table 1 Objectives and Corresponding Endpoints (cont.)
7.To investigate the relationship between 
plasma concentrations of moxifloxacin 
and QTcF interval length (if warranted) .7.Pharmacokinetic -pharmacodynamic model of 
moxifloxacin concentrations vs. QTcF ch anges
(if warranted)
8.To investigate the ECG assay sensitivity 
to detect a change in the QTcF interval, 
using moxifloxacin 400 mg as an active 
control.8.Placebo -corrected, change -from-baseline QTcF 
(QTcF) measured on 12 lead ECGs extracted 
from continuous recordings at the specified time 
points on Day 2 and Day 15
9.To investigate the safety and tolerability 
of balovaptan and moxifloxacin at the 
dosing regimens scheduled.9.Safety assessments: adverse events , physical 
examination , vital signs , laboratory tests , 
C-SSRS , and heart rate (HR) monitoring .
Exploratory Objective s Corresponding Endpoints
1.To investigate any effect of balovaptan 
at [ADDRESS_1008016] of 50 mg qd 
and 10 mg qd on right and left heart as 
assessed by [INVESTIGATOR_118059] -Doppler echo.1.TT-Doppler echocardiography: pulmonary arter y 
acceleration time (PAAT), right ventricular 
outflow tract -velocity time integral (RVOT -VTI) 
and deriv ed mean pulmonary arterial pressure as 
change to baseline relative to placebo 
treatment .(objectives 1 & 2)
2.TT-Doppler -echocardiography: LVEF and 
additional secondary TT -Doppler -
echocardiography parameters of left and right 
heart, as described in Section 4.5.7 (objectives 1 
& 2)
3.To investigate the effect 10 mg and 50 
mg QD balovaptan on blood pressure 
and heart rate as measured by [CONTACT_737760]-ECG and ABPM .3.Ambulator y blood pressure monitoring (ABPM): 
mean diastolic and systolic blood pressure 
(daytime and nighttime mean).
Heart rate will also be analyzed as 
derived from Holter ECG .
-Heart rate as derived from ABPM 
and/or Holter ECG may  be 
explored against fluctuations in 
blood pressure measured by 
[CONTACT_44117] (if warranted).
4.To investigate whether genetic variants 
in genes are associated with natural or 
potential drug induced neutropenia; with 
differences in pharmacokinetics of 
balovaptan, M2 or M3, or with any 
potential effect of balovaptan on ECG 
parameters. 4.The genetic variants in genes that are associated 
with natural or potential drug induced 
neutropenia; genetic variants in genes that are 
associated with pharmacogenetics of 
metabolizing enz ymes, transferases, 
transporters, etc, (eg,CYP3A4 and P -
glycoprotein); genetic variants in genes that may  
be associated with a potential effect of 
balovaptan on ECG parameters.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
31/Protocol WP40734 , Version 3.03. STUDY DESIGN
3.[ADDRESS_1008017] 
of balovaptan on the QTc interval in healthy subjects.
Screening
Screening will be conducted up to 28 and 3days (inclusive) before each subject’s first 
dosing day (Day 1 of Treatment Period 1).
In-Clinic Confinement
Day -2
Subjects will be confined to the CRU starting on Day -2until the morning of Day16 
during each Treatment Period. Subjects are entered into CRU on Day -2so that 
subjects are rested and prepared for the baseline ABPM and baseline TT -Doppler
echocardiogram onDay-1. Eligibility assessments will be performed on Day -2as 
outlined in the Schedule of Activities (SoA) ,Appendix 1.
Day -1
On Day -1of each Treatment Period, ABPM and TT -Doppler echocardiogram
assessments will be performed .These results will serve as the baseline for the subjects .
On days when TT-Doppler echocardiogram and ABPM assessments are performed 
subjects will be given low salt standardized me als.
Randomization (Day  -1)
At the start of thestudy Treatment Period 1, at the end of the day o fDay-1, subjects will 
be randomized to one of the 12treatment sequence scomprised of the 4 treatment s 
described:
Treatment s
Treatment A(balovaptan therapeutic dose)
Days 1-14: A single once daily oral dose of 10 mg (1 × 10 mg tablet) of balovaptan and 4 
tablets of matching placebo for balovaptan for 14 days.
Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
32/Protocol WP40734 , Version 3.0Treatment B(balovaptan supra -therapeutic dose)
Days 1-14: Asingle once daily oral dose of 50 mg (5 x 10 mg table ts) of balovaptan for 
14days.
Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Treatment C (active control [400 mg moxifloxacin] on Day  2)
Days 1-14: A single once daily oral dose of 5 tablets of matching placebo for balovaptan for
14days.
Day 2: A single oral dose of 400 mg moxifloxacin capsule
Day 15: A single oral dose of a matching placebo capsule for moxifloxacin 
Treatment D (active control [400 mg moxifloxacin] on Day  15)
Days 1-14: A single once daily oral dose of 5 tablets of matching placebo for balovaptan for
14days.
Day 2: A single oral dose of a matching placebo capsule for moxifloxacin
Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Treatment Sequences
1.A, B, C
2.A, C, B
3.B, A, C
4.B, C, A
5.C, A, B
6.C, B, A
7.A, B, D
8.A, D, B
9.B, A, D
10.B, D, A
11.D, A, B
12.D, B, A
Dosing (Day s 1-15)
Each Treatment Period will involve 15days of dosing (Day 1 –Day15). Subjects must 
fast for at least 8 hours prior to and 4 hours after dosing on study days when 24-hour 
Holter ECG assessment s will be performed (study Days 1, 2, 14 and 15). Dosing on 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
33/Protocol WP40734 , Version 3.0study days with 24-hour Holter ECG assessment should be at approximately the same 
time of day ±1h.
Prior to dosing on Day 1 subjects will undergo pre -dose assessment s as outlined in the 
SoA (Appendix 1). Following pre -dose assessments s ubjects will receive a single dose 
of study medication preceded by a ≥[ADDRESS_1008018]. If subjects 
require more liquid to take all study drugs, additional water may be provided in aliquots 
of 50mL.If additional water is provided the amount should be captured. Water 
provided for study drug administrat ion will be identical on all dosing days. Identical 
fasting procedures from Day 1 will be followed on study Days 2, 14 and 15. No fasting 
will be required on other dosing days. Subjects will receive standardized low salt meals 
on study days when 24- hour Holter ECGs (Days 1, 2, 14 and 15), ABPM (Days -1 
and12) or TT -Doppler echocardiogram (Days -1 and 13) assessments will be performed.  
Meals will be given at approximately the sa me time on each of these study days.
Days 1 and 2 : 24-hour Holter ECG A ssessments
On study Days 1 and 2 ,of each Treatment Period ,24-hour ECG assessments will be 
performed . Subjects will be administered s tudy drug following a ≥[ADDRESS_1008019] -dose 
assessments as outlined in the SoA (Appendix 1).
Day [ADDRESS_1008020] -dose 
assessments as outlined in the SoA (Appendix 1).
Day [ADDRESS_1008021] -dose assessments as outlined in the SoA (Appendix 1).
Days 14 and 15 -24-hour Holter ECG A ssessments
On study Days 14 and 15 of each Treatment Period ,24-hour ECG assessments will be 
performed. Subjects will be administered study drug following a ≥[ADDRESS_1008022] swill be provided with standardized 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
34/Protocol WP40734 , Version 3.0low salt meals on these days. Subjects will undergo pre and post -dose assessments as 
outlined in the SoA (Appendix 1).
Day 16
Subjects will be discharged from the CRU on the morning of Day 16 after final 
assessments as described in the SoA (Appendix 1).
Wash out Period :
Following each Treatment Period subjects will undergo a washout period lasting a 
minimum of [ADDRESS_1008023] dose of study drug.
Follo w-up:
Subjects will return to the unit for a follow -up visit between 14 and 21 days after the final 
dose of study drug. This will include a general physical examination, 12 -lead ECG, vital 
signs , C-SSRS, adverse event review, body weight and laboratory safety tests.
Figure 1presents an overview of the study design.  ASoA is provided in Appendix 1.
Figure 1 Study Schema

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
35/Protocol WP40734 , Version 3.03.[ADDRESS_1008024] the duration of 
the study from S creening to the end ofFollow -upwill be a m inimu m of 122days or a
maximum of 143days .
Screening: up to 28 days
Dosing periods including washout: 80 -94days
oTreatment Period 1 : 18Days (Day-2 –Day16)
oWashout :13-20 Days
oTreatm ent Period 2: 18Days (Day -2 –Day16)
oWashout : 13-20Days
oTreatment Period 3: 18Days (Day -2 –Day16)
Follow up: [ADDRESS_1008025] potential ECG effects of balovaptan .Moxifloxacin, 
a fluoroquinolone antibiotic ,when utilized at therapeutic doses (400 mg) isassociated 
with QT prolongation and regulatory authorities have recommended it as a positive 
control to evaluate the sensitivity of clinical studies designed to detect small but 
significant increases in QT interval measurements .4
Across clinical trials, no balovaptan associated changes in blood pressure orHRare
apparent. Therefore , this study uses QTcF as primary parameter rather than an 
individualized corrected QTc. Since a cross -over design corrects for diurnal fluctuations 
of QTc, a separate Day -1 reading is not needed, 3 time points (replicates at each time 
point) pre-dose ar e used as baseline.
3.3.1 Rationale for Balova ptan and Moxifloxacin Dose and Schedule
[IP_ADDRESS] Balovaptan
A dose of 10 mg balovaptan has shown statistically significant changes in efficacy 
parameters in adult male patients with ASD (Phase 2) and is the current recommended 
Phase 3dose.
Balovaptan is being developed for use in ASD, so it is expected that patients will need to 
take it for prolonged periods of time, likely for years or for their lifetime. Hence multiple 
dose testing is relevant from a clinical point of view. The multiple dose PK of balovaptan 
with 14 days of dosing was previously characterized in humans and was found to be 
time-dependent. Accumulation was observed with multiple dosing, and steady state of 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
36/Protocol WP40734 , Version 3.0balovaptan was observe d after approximately [ADDRESS_1008026] of balovaptan on cardiac 
repolarization by [CONTACT_737767] -
therapeutic doses. To this end s ubjects will be dosed once daily with balovaptan for 
14 days at either theprojected therapeutic dose of 10mg or a supra -therapeutic dose of 
50mg and ECG parameters monitored.
In the MAD part of study BP25694 multiple doses of 12 mg (just above the clinical dose 
of 10mg)resulted in a Cmax of 99 ng/mL. In Study BP28977 co- administration of 
itraconazole led to a 36% increase in C max . In the MAD part of study BP25694 multiple 
doses of 52 mg qd in healthy subjects were well tolerated and resulted in a Cmax of 
484ng/mL. In light of convulsions observed in dogs, dose escalation in study BP25694 
was stopped so as not to exceed a C max of 810 ng/mL. In conclusion, based on 
previous clinical experience aonce -daily dose of 50mg balovaptan for 14days is 
expected to be well tolerated considering the short duration of dosing in this study. 
[IP_ADDRESS] Moxifloxacin
The study will utilize moxifloxacin (400mg) as apositive -control to assure the study as 
designed will be able to detect potential ECG effects of balovaptan. Moxifloxacin, a 
fluoroquinolone antibiotic, when utilized at itsrecommended therapeutic dose of 400mg
qdis associated with QT prolongation .Regulatory authorities have recommended 
moxifloxacin as a positive control to evaluate the sensitivity of clinical studies designed 
to detect small but significant increases in QT interval measurements. Subjects will 
receive 400 mg oral moxifloxacin in a nested cross -over fashion using a joint 
placebo /positive control period. In this period, half of the subjects will be dosed with 
moxifloxacin on Day [ADDRESS_1008027] been chosen as 
the study population due to the low risk of clinically significant toxicity at anticipated 
exposure levels. Moreover, use of healthy subjects, as opposed to patients, will allow a 
clearer interpretation of the study results, as there will be no confounding factors that 
result from changes in disease state and/or concomitant medication use.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
37/Protocol WP40734 , Version [IP_ADDRESS] Rationale for Transthoracic Doppler -echocardiogram and 
Ambulatory  Blood Pressure Monitoring
As an exploratory marker transthoracic Doppler echo -cardiography is included to 
estimate pulmonary blood pressure with the a priori expectation that no changes in 
pulmonary circulatory dynamics will be seen.
In animals as well as preparations of pulmonary vasculature, vasopressin has been 
shown to decrease pul monary blood pressure and to relax arterial constriction through 
V1a receptors and in animals these changes were accompanied by [CONTACT_737768] .8,9However, GLP toxicology animal studies with balovaptan have 
not pointed to a right heart challenge strain nor to pulmonary fibrosis. No systemic blood 
pressure changes with balovaptan were noted in clinical studies.
In clinical trials, blood pressure monitoring has not revealed apparent blood pressure 
changes. However, blood pressure monito ring focused on few time points around 
pharmacokinetic Tmax and no night -time blood pressure data are available. Hence, 
ABPM is included in this study to supplement the existing blood pressure profiling, 
exploring in a more intense way any effects of balo vaptan on daytime blood pressure
(9:00 am to 9:00 pm)and to collect data for nighttime blood pressure (1:00 am to 
5:30 am).
This study provides an opportunity for these exploratory measures considering a 
homogeneous population of healthy volunteers and the inclusion of a multiple dose 
higher than the dose of [ADDRESS_1008028] 
1/3 male subjects by [CONTACT_151073] a minimum of 40% of enrolled population are male .
Initially 56subjects will be enrolled with the goal of obtaining 4 8evaluable subjects.
Enrolled subjects who w ithdraw from the study may be replaced at the discretion of the 
Investigator (or designee )and Sponsor to ensure adequate numbers of evaluable 
subjects.
4.1.[ADDRESS_1008029] meet the following criteria for study entry:
1.Healthy male or female volunteers aged 18 to 60years inclusive, at Screening. 
Healthy status is defined by [CONTACT_737769] a detailed medical and surgical history, a complete physical 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
38/Protocol WP40734 , Version 3.0examination including v ital signs, 12 -lead ECG, hematology, blood chemistry, 
urinalysis, and serology.
2.Body Mass Index (BMI) between 18 and 32 kg/m2inclusive, at Screening.
3.For women of childbearing potential: agreement to use at least [ADDRESS_1008030] dose of 
study drug.
a.A woman is considered to be of childbearing potential if she is 
postmenarcheal, has not reached a postmenopausal state ( >12 
continuous months of amenorrhea with no identified cause other than 
menopause), and has not undergone surgical sterilization (removal of 
ovaries and/or uterus).
b.The following are acceptable contraceptive methods: abstinence from 
heterosexual activity ;bilateral tubal ligation; sterilization of male ‘partner; 
hormonal contraceptives; hormone -releasing intrauterine devices; copper 
intrauterine devices; Essure .
c.Barrier methods alone are not considered an acceptable form of 
contraception for this study and if utilized must be supplemented by [CONTACT_737770] d escribed above. For this study barrier 
contraception methods are defined as: male or female condom with or 
without spermicide (male and female condom must not be used 
simultaneously); and cap, diaphragm, or sponge with spermicide.
4.For men: Vasectomized , agreement to remain abstinent (refrain from 
heterosexual intercourse) or use of a condom during intercourse. Must also 
agree to refrain from donating sperm, as defined below:
a.With female partners of childbearing potential or pregnant female partners, 
men m ust remain abstinent or use a condom during the entire study and 
for [ADDRESS_1008031] refrain from donating sperm during this same period.
5.Able to participate, and willing to give written informed consent and to comply 
with the study restrictions.
6.Fluent in English .
4.1.2 Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from study entry:
Past Medical History
1.History of any clinically significant gastrointestinal , renal, hepatic, broncho -
pulmonary, neurological, psychiatric, cardiovascular, endocrinological, 
hematological, lymphatic, musculoskeletal, genitourinary, immunological, 
dermatological or connective tissue or allergic disease, metabolic disorder, or 
cancer.
2.Signs and symptoms potentially indicative of peripheral neuropathy .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
39/Protocol WP40734 , Version 3.03.Unexplained orthostatic reaction with syncope within last 6months .
4.A history of clinically significant hypersensitivity (e .g., to drugs, including 
moxifloxacin or any quinolone antibio tics and balovaptan, and excipi[INVESTIGATOR_840]) or allergic 
reactions .
5.History of alcohol and/or drug abuse or addiction within the last 2years before study 
enrollment .
6.Subjects on hormone replacement therapy if post -menopausal status cannot be 
documented from medic al history.
7.Previous treatments with iron for iron deficiency anemia within three months of 
screening.
8.History of coagulopathies, bleeding disorders, or blood dyscrasias.
9.History of porphyria, active liver disease or permanent or unexplained elevation of 
serum transaminases.
10.In the opi[INVESTIGATOR_25279], any major illness within one month 
before the Screening examination or any febrile illness within one week prior to 
Screening and up to first study drug administratio n.
Current S tatus
1.Clinically relevant deviation from normal in the physical examination including 
vitalsigns.
2.Positive result on human immunodeficiency virus (HIV )1, HIV 2, hepatitis C virus 
(HCV) antibody, or hepatitis B virus surface antigen (HBsAg).
3.Clinically signific ant abnormalities in laboratory test results (including complete 
blood count, chemistry panel, and urinalysis). In the case of uncertain or 
questionable results, tests performed during Screening may be repeated on Day -[ADDRESS_1008032] at screening or prior to Day 1of any Treatment 
Period.
5.Lactating women .
6.Any condition or disease detected during the medical interview / physical 
examination that would render the subject unsuitable for the study, place the subj ect 
at undue risk or interfere with the ability of the subject to complete the study in the 
opi[INVESTIGATOR_25279].
7.Subjects with CPK values > 2x upper limit of normal (ULN), confirmed by [CONTACT_125091] .
8.Positive urine alcohol test or urine drug testat screening or Day -2of each 
treatment period ( amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids ,
cocaine, opi[INVESTIGATOR_858] ,methadone, methamphetamines, and
3,4-methylenedioxymethamphetamine [MDMA ]).
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
40/Protocol WP40734 , Version 3.09.Subject h asbeen a r egular smoker (> 5 cigarettes, > 1 pi[INVESTIGATOR_737735] , >1 cigar per day or 
equivalent as determined by [CONTACT_368120] )within 6 months of study 
enrollment .
10.Coffee (or tea) consumption > 5cups per day or methylxanthine -containing 
drinks > 1.5liter/day or more than 250 g/day of chocolate within [ADDRESS_1008033] 
dose of study drug . 
11.Alcohol consumption of > 18units per week for males and females. One unit of 
alcohol equals [ADDRESS_1008034] or donated in excess of ~450 mL blood in the 3 months prior 
to Day 1 of Treatment Period 1.
13.Subjects under judicial supervision, guardianship, or curatorship .
14.Dietary restrictions that would prohibit the consumption of standardized meals .
15.Poor venous access for blood sampling.
Concomitant Medication
1.Taken g reater than 2 g/day paracet amol within 48 hours of study drug administration
or greater than 4 g/day paracetamol within [ADDRESS_1008035] dose administration are excluded , unless in the opi[INVESTIGATOR_684] (or designee )the medication will not interfere with the study procedures 
or compromise safety . 
6.Any slow release medicinal formulations considered to still be active within 4weeks 
(or within 5times the elimination half -life of the medication, whichever is longer) pr ior 
to the first study drug administration are prohibited, unless in the opi[INVESTIGATOR_737739] .
7.Taking any inhibitor of CYP3A taken within 4 weeks (or within 5half-lives, whichever 
is longer) prior to study drug administration ortaking any inducer of CYP3A within 
4weeks of the first dose of study drug.
8.Use of any prohibited medications and food before study start and subjects who do 
not agree to refrain fro m consuming prohibited medications or food during the study.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
41/Protocol WP40734 , Version 3.09.Subjects who have previously enrolled in, or withdrawn after enrollment, from this 
study .
TQT-related Exclusion Criteria :
1. Personal history of unexplained black -outs or faints.
2.Personal history of reactions or faints at having their blood taken, unexplained 
black -outs or faints or any condition which could relapse during or immediately after 
the study which in the opi[INVESTIGATOR_737740] i n this study.
3.Subjects experiencing fainting or pre -syncopal events during orthostatic challenge 
testing ,performed according to site SOP, at Screening and Day -2 of Treatment 
Period 1.
4.Subjects with Screening or Treatment P eriod 1 (Day -2)baseline mean QT interval 
corrected using Fridericia’s formula (QTcF) >450msor <300ms(using the same 
upper QTcF limit in both males and females) or > 30msdifference between the 
highest and the lowest readings of the triplicate ECGs recorded .
5.Scree ning or baseline (Day -2Treatment Period 1) ECG evidence of atrial fibrillation, 
atrial flutter, second or third -degree AV block, complete right or left bundle branch 
block, Wolff-Parkinson -White-syndrome, or cardiac pacemaker.
6.Screening or baseline ECGs (Day -2 of Treatment Period 1) with QRS and/or 
T-wave judged to be unfavorable for a consistently accurate QT measurement (i .e., 
neuromuscular artifact that cannot be readily eliminated, arrhythmias, indistinct QRS 
onset, low amplitude T -wave, merged T -and U -waves, prominent U -waves, etc.).
7.Confirmed (based on the average of ≥3 consecutive measurements) systolic blood 
pressure greater than 139 or less than 90 mmHg, and diastolic blood pressure 
greater than 89 or less than 45mmHg at Screening and Day -2 of Treatment Period 
1.
8.Confirmed (based on the average of ≥3 consecutive measurements) resting 
HR>100bpm or <40bpm atScreening or Day -2of Treatment Period 1.
9.Notable resting bradycardia (HR <40bpm) on ECG atScreening or Day-2 of 
Treatment Period 1. Notable resting tachycardia (mean HR >100bpm) on ECG at 
Screening or Day -2of Treatment Period 1.
10.Family history of congenital long QT syndrome or sudden death.
11.History or presence of clinically significant ECG abnormalities , as determined by 
[CONTACT_737771] ,before study drug administration.
4.[ADDRESS_1008036] met all eligibility criteria will receive a 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
42/Protocol WP40734 , Version 3.0randomization number on Day -1of the first treatment period and according to the 
randomization code generated by [CONTACT_737772]. The 
randomization number will ensure identification throughout the study. Replacement 
subjects will receive the randomization number of the subject to be replaced, increased 
by 1000 (e.g. , 1101 replacement number for randomization number 101), and will be 
administered the same treatment.
Subjects who drop out or withdraw for any reason without completing all screening
evaluations successfully, will be considered “screening failures”. Such subjects will not
receive a randomization number, and only applicable data will be entered in the 
electronic case report forms (eCRFs).
Subjects will be randomly assigned to one of the 12treatment sequences according to 
therandomization code.
4.2.2 Blinding
The following controls will be employed to maintain the double -blind status of the study .
A double dummy design will be used, a ll treatments are blinded ( balovaptan and 
matching placebo, moxifloxacin andmatching placebo). Groups will receive placebo
and study drugs as described in Section 3.1. The oral tablets/capsules will be 
indistinguishable in appearance and taste to balovaptan andmoxifloxacin, respectively.
The number of tablets and capsules will be identical for each subject regardless of 
treatment and dose.
Study site personnel (with the exception of the unblinded pharmac y staff ) and subjects
will be blinded to treatment assignment during the study.  The Sponsor and its agents 
will also be blinded to treatment assignment, with the exception of individuals who 
require access to subject treatment assignments to fulfilltheir job roles during a clinical 
trial.
As per health authority reporting requirements, the Sponsor 's Drug Safety representative
will break the treatment code for all serious, unexpected suspected adverse reactions
that are considered by [CONTACT_737773].  The subject may continue to receive treatment, and the Investigat or or designee, 
subject, and Sponsor personnel, with the exception of the Drug Safety representative 
and personnel who must have access to subject treatment assignments to fulfill their 
roles (as defined above), will remain blinded to treatment assignment.
4.3 STUDY TRE ATMENT AND OTHER TRE ATMENTS RELEVA NT 
TO THE STUDY DESIGN
The investigational medicinal products (IMPs) for this study are balovaptan ,moxifloxacin
and placebo .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
43/Protocol WP40734 , Version [IP_ADDRESS] Study Treatment Formulation, Packaging, and Handling
[IP_ADDRESS] Balovaptan and Placebo
RO5285119/F17 [ADDRESS_1008037] label . For additional details, refer to the balovaptan Investigator's 
Brochure.
[IP_ADDRESS] Moxifloxacin Active Control and Placebo
Moxifloxacin (400mg qd, administered as 400mg over-encapsulated tablets ) will be 
supplied by [CONTACT_1034] .The over-encapsulated moxifloxacin and matching placebo
must be stored and handled according to the details specified on the product label .
4.3.[ADDRESS_1008038] administration of any of the study treatments should be noted 
on the Study Drug Administration electronic Case Report Form (eCRF) .In this study an 
overdose is defined as any dose of balovaptan gr eater than [ADDRESS_1008039] administration of any of the study treatments should be recorded 
on the Adverse Event Report Form.
Guidelines for treatment interruption or discontinuation for subjects who experience 
adverse events are provided in Section 5.1.
[IP_ADDRESS] Balovaptan and Placebo
Treatment A:A single once daily oral dose of 10 mg (1 × 10 mg tablet) of balovaptan 
and 4 tablets of matching placebo for balovaptan for 14 days.
Treatment B:A singl e once daily oral dose of 50 mg (5 x 10 mg tablets) of balovaptan 
for 14 days.
Treatment C:A single once daily oral dose of 5 tablets of matching placebo for
balovaptan for 14 days.
Treatment D: A single once daily oral dose of [ADDRESS_1008040] bo for 
balovaptan for 14 days
Doses of balovaptan, and matching placebos on Days 1, 2, 14 or 15 will be administered 
with approximately 240 mL of water (at room temperature) after at least 8 hours of 
fasting. Dosing on these days will be at approximately the same time of day ± 1h. 
Post-dose subjects will maintain a [ADDRESS_1008041] during which no food will be allowed.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
44/Protocol WP40734 , Version 3.0While in the clinical research unit, subjects will be allowed to consume water ad libitum, 
except for 2 hours before and 2 hours after oral dos ing.However, excessive 
consumption of liquids should be avoided (Section 4.4.4 ).Liquids are permitted with the 
breakfast meal on non -fasting days .
[IP_ADDRESS] Moxiflo xacin (Active Control) and Placebo
Treatment A:A single oral dose of a matching placebo capsule for moxifloxacin on 
Day2 and 15.
Treatment B: A single oral dose of a matching placebo capsule for moxifloxacin on 
Day2 and 15.
Treatment C:A single oral dose of 400 mg moxifloxacin capsule on Day 2.A single oral 
dose of a matching placebo capsule for moxifloxacin on Day 15.
Treatment D:A single oral dose of a matching placebo capsule for moxifloxacin on 
Day2.A single oral dose of 400 mg moxifloxacin capsule on Day15.
Themoxifloxacin and matching placebos on Day 2 and 15 will be administered with 
approximately 240 mL of water (at room temperature) after at least 8 hours of fasting.
On Day 2, moxifloxacin or matching placebo will be administered immediately after the 
balovaptan or placebo dose with the same 240 mL of water . Dosing on these days will 
be at approximately the same time of day ±1h.Post-dose subjects will maintain a
4-hour fast during which no food will be allowed.
4.3.[ADDRESS_1008042] A ccountability
Balovaptan and placebo will be provided by [CONTACT_1034]. The study site will 
acknowledge receipt of IMPs supplied by [CONTACT_737774]. Any damaged 
shipments will be replaced. Moxifloxacin and matching placebo will be provided by [CONTACT_429] .
The IMPs will either be disposed of at the study site according to the study site’s 
institutional standard operating procedure or be returned to the Sponsor with the 
appropriate documentation. The site’s method of destroying Sponsor -supplied IMPs 
must be agreed to by [CONTACT_1034]. The site must obtain written authorization from the 
Sponsor before any Sponsor -supplied IMP is destroyed, and IMP destruction must be 
documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
[CONTACT_25729].
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
45/Protocol WP40734 , Version 3.04.4 CONCOMITA NT THERA PY,PROHIBITED FOOD, A ND 
ADDITIONA L RESTRICTI ONS
Concomitant therapy consists of any medication (e.g., prescription drugs, 
over-the-counter drugs, vaccines, or homeopathic remedies, nutritional supplements) 
used by a subject in addition to protocol -mandated treatment from 30 days prior to 
initiation of study drug to the study completion/ discontinuation visit. All such 
medications should be reported to the Investigator or designee and recorded on the 
Concomitant Medications eCRF.
4.4.[ADDRESS_1008043] of the study. Women of childbearing potential: 
agreement to use at least [ADDRESS_1008044] dose of study drug.
Acetaminophen/paracetamol is allowed up to a maximum dose of 4g/day within 7days 
before study drug administration and 2 g/day within [ADDRESS_1008045] study drug administration through follow -up.
Any slow release medicinal formulations considered to still be active within 4 weeks (or 
within 5 times the elimination half -life of the medication, whichever is longer) prior to the 
first study drug administration are prohibited, unless in the opi[INVESTIGATOR_737741] p rocedures or compromise 
safety.
Any prescribed systemic or topi[INVESTIGATOR_737742] 14days prior to 
the first dose of study drug through the follow -up visit (with the exception of permitted 
therapi[INVESTIGATOR_737743] 4.4.1 ).
Additional exception smaybe made formedications to treat AEs ,ifthe rationale for the 
exception is discussed and approved by[CONTACT_24342] (or designee )as well as the 
[COMPANY_002] medical monitor s.All medication administered to manage AEs should be 
recorded on the Adverse Event Report Form.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
46/Protocol WP40734 , Version 3.0The following concomitant medications in particular are prohibited, unless an exception 
has been agreed to by [CONTACT_737] (or designee ),and the [COMPANY_002] medical monitor s.
Any inhibitor of CYP3A taken within 4 weeks (or within 5 half -lives, whichever is 
longer) prior to study drug administration, including but not limited to the following 
drugs: ketoconazole, miconazole, itraconazole, fluconazole, erythromycin, 
clarithromycin, ranitidine, and cimetidine, until follow -up.
Any inducer of CYP3A taken within 4weeks prior to study drug administration, 
including but not limited to the following drugs: rifampi[INVESTIGATOR_2513], rifabutin, glucocorticoids, 
carbamazepi[INVESTIGATOR_050], phenytoin, phenobarbital and St. John's wort, until follow -up.
4.4.3 Prohibited Food
Consumption of methylxanthine- containing products (e.g., coffee, tea, cola, 
chocolate) will be forbidden from 48 hours prior to Day-2check -in to CRU and 
during the stay .
It is not permitted to take any nutrients known to modulate cytochrome CYP3A 
activity (e.g., grapefruit juice; S eville orange) within [ADDRESS_1008046] dosing until 
discharge from the CRU at the end of the study.
Subjects should refrain from consumption of any foods containing poppy seeds 
within 48 hours (2 days) prior to screening and each admission to the clinical 
research center to avoid false positive drug screen results.
Alcohol consumption will not be allowed 48 hours before Day -2admission to CRU 
and while staying in the CRU
4.4.4 Additional Restrictions/Considerations
While in the clinical research unit, subjects will be allowed to consume water ad 
libitum, except for 2 hours before and 2 hours after oral dosing .Subjects will be 
provided guidance at CRU Admission, for each Treatment Period, that they should 
avoid excessive fluid intake during the study. Excessive fluid intake for this study is 
defined as 3 L (100 floz.) per day.  Clinic staff will provide guidance as to 
approximate number of drinks in [ADDRESS_1008047] fluid 
intake.
Subjects must fast for at least 8 hours prior to and 4 hours after dosing on Days 1, 2, 
14, and 15. Dosing on these days will be at approximately the same time of day (±
1h). Standardized low salt meals should be provided at approximately the same 
time of day on Days -1,1, 2,12, 13, 14 and 15 .
Between the screening visit and follow -upvisit, alcohol must be restricted to no 
more than 2 drinks per day ( one drink is equal to 12 ounces of beer, 5 ounces of 
wine or 1.5 ounces of 80 proof spi[INVESTIGATOR_2120] ). Alcohol consumption will not be allowed 
48hours before Day-2admission to the CRU and while staying in the CRU. 
Additional alcohol/drugs of abuse testing may be employed throughout the study to 
verify compliance.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
47/Protocol WP40734 , Version 3.0Use of tobacco will not be permitted 48 hours prior to admission and until discharge 
from the CRU in each study period.
Subjects should refrain from strenuous exercise for at least 96 hours prior to dosing
until discharge from the CRU at the en d of the study.
[IP_ADDRESS] Herbal Therapi[INVESTIGATOR_737744] [ADDRESS_1008048] be obtained before 
performing any study -related procedures (including screening evaluations) .  Informed 
Consent Forms for enrolled subjects and for subjects who are not subsequently enrolled 
will be maintained at the study site.
All screening evaluations must be completed and reviewed to confirm that subjects meet 
all eligibility criteria before enrollment .  The Investigator or designee will maintain a 
screening log to record details of all subjects screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
4.5.2 Medical History , Concomitant Medication, and Demographic 
Data
Medical history, including clinically significant diseases, surgeries, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), reproductive status, smoking 
history, and use of alcohol and drugs of abuse, will be recorded at baseline.  In addition, 
all medications (e.g., prescription drugs, over -the-counter drugs, vaccines, or 
homeopathic remedies, nutritional supplements , or herbal ) used by [CONTACT_2690] 
30days prior to initiation of study treatment will be recorded. Any nonprescribed 
systemic or topi[INVESTIGATOR_737745] [ADDRESS_1008049] study drug administration through Follow -up.At the time of each Follow -up visit 
physical examination, an interval medical history should be obtained and any changes in 
medications and allergies should b e recorded.
Demographic data will include age, sex, and self -reported race/ethnicity.
4.5.3 Physical Examinations
A complete physical examination, performed at Screening and other specified visits
(Appendix 1), should include an evaluation of the head, eyes, ears, nose, and throat, 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
48/Protocol WP40734 , Version 3.0and the cardiovascular, dermatologic , musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, 
genitourinary (at Investigator or designee ’s discretion) .  Any clinically significant 
abnormality identified at baseline should be recorded on the General Medical History 
and Baseline Conditions eCRF.   Changes from baseline abnormalities should be 
recorded in subject notes.  New or wors ened clinically significant abnormalities should 
be recorded as adverse events on the Adverse Event eCRF and source form .
4.5.4 Vital Signs
Oral body temperature, pulse rate, and supi[INVESTIGATOR_737746] ( Appendix 1).ABPM assessment will be performed on study 
Days -1and 12.
4.5.[ADDRESS_1008050] to the confidentiality standards 
described in Section 8.4.
[IP_ADDRESS] Laboratory  Samples
Laboratory samples will be collected at the time points indicated in the SoA ( Appendix 1). 
Samples will be collected at Screening, Day -2, Day 3, Day7,Day15and Follow -up visit
for each Treatment Period .Additional blood or urine samples may be taken at the 
discretion of the Investigator or designee if the results of any test fall soutside the 
reference ranges, or clinical symptoms necessitate additional testing to monitor subject 
safety. Subjects must fast for at least 8 hours prior to laboratory safety assessments
(except for urine assessments) .
Samples for the following laboratory tests will be sent to the study site’s local laboratory 
for analysis:
Hematology: leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, absolute 
and percent differential W BC count (neutrophils, eosinophils, basoph ils, monocytes, 
lymphocytes) .
Urinalysis: A midstream, clean -catch urine specimen will be collected for dipstick 
analysis of pH, glucose, leukocytes, nitrites, protein and blood. Microscopy will be 
performed if abnormalities are observed in initial analys is.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
49/Protocol WP40734 , Version 3.0Coagulation: prothrombin time (international normalized ratio) and activated 
thromboplastin time .
Blood chemistry panel: sodium, potassium, glucose (fasting), creatinine, total and 
conjugated bilirubin, alkaline phosphatase, alanine aminotransferase (A LT), 
aspartate aminotransferase (AST), gamma- glutamyl transferase, creatine 
phosphokinase (CPK) and l actate dehydrogenase (LDH) .
Biomarkers fo r cardiac damage: samples will be taken for troponin I,cardiac 
troponin T (cTnT) and N-terminal pro b-type natriuretic peptide (NT- proBNP) but 
these samples will be stored, and assays only run if requested for specific subject (s)
due to concerns regarding cardiac safety.  
Drugs of abuse (including amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_737747], cocai ne, opi[INVESTIGATOR_858], methamphetamines, methadone and 
3,4-methylenedioxymethamphetamine (MDMA) , will be measured in urine at 
Screening and on Day -2of each Treatment Period.   Further testing may be 
performed throughout the study to confirm compliance at the discre tion of the 
Investigator or designee.
Urine alcohol test at Screening and on Day -2of each study period.   Further testing 
may be performed throughout the study to confirm compliance at the discretion of 
the Investigator or designee.
Viral serology: human immunodeficiency virus (HIV) -1 and -2 antibodies, hepatitis 
C antibody, hepatitis B surface antigen and hepatitis C virus (HCV) antibody will be 
assessed at Screening.
Pregnancy test: beta -human chorionic gonadotropin (serum pregnancy test) will be 
perfo rmed at Screening and Day -2forall female subjects at Treatment Period 1 
and Day -2 for subsequent Treatment Periods .
Follicle -stimulating hormone (FSH)will be assessed at Screening for all females
[IP_ADDRESS] Pharmacokinetic Samples
Pharmacokinetic samples will be taken via an indwelling catheter or by [CONTACT_737775] 1andAppendix 2.
Three (3) aliquoted plasma samples will be prepared for each time point . Two (2) of the
aliquoted PK plasma samples will be shipped to the designated bioanalytical laboratory 
for analysis. Thethird aliquot will be frozen and stored at PRA ( -80°C ) for up to 2 years 
after issue of the CSR to allow for repeat analysis if required.
For additional sampling procedures, storage conditions, and shipment instructions, see 
the Laboratory Manual.
[IP_ADDRESS] Optional Samples for genetic analy ses
An optional whole blood sample will be taken for DNA extraction and clinical genotypi[INVESTIGATOR_737748]. See Appendix 1 for collection 
timepoint and associated footnote.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
50/Protocol WP40734 , Version 3.0The DNA may be used for:
 
oto determine if genetic variants of cytochrome P450s (e.g., CYP3A4), 
transporters, or receptors may affect the metabolism, pharmacokinetics of 
balovaptan, or be associated with any potential effect on ECG parameters .
This sample may be stored for up to two years foll owing the issue of the CSR.
Data arising from all biosamples including samples for analyses of inherited DNA will be 
subject to the confidentiality standards described in Section 8.4 .
4.5.6 Electrocardiograms
Safety and diagnostic ECG assessments will be perfo rmed in this study.
[IP_ADDRESS] 12-lead Safety  Electrocardiograms
Safety ECGs will be performed at defined time points (Appendix 1).Safety ECG 
performed at Screening and Day -2 of each treatment period will be done in triplicate. All 
other safety ECG readings will be single recordings .These ECG recordings will only be
used to assess /define a safety baseline and determine the immediate safety of each 
subject during each Treatment Period .Safety ECG recordings may be obtained at 
unscheduled timepoints as required by [CONTACT_737] ,or designee, to ensure the 
safety of study subjects .For safety monitoring purposes, the Investigator ,or designee ,
must review, sign, and date all ECG tracings.
All safety ECG recordings must be performed using a standard high -quality, high- fidelity 
digital electroc ardiograph machine equipped with computer -based interval 
measurements.  Lead placement should be as consistent as possible.  ECG recordings 
must be performed after the subject has been resting in a supi[INVESTIGATOR_21683] 10 
minutes.  All ECGs are to be obtained prior to other procedures scheduled at that same 
time (e.g., vital sign measurements, blood draws) and should not be obtained within 
3hours after any meal , when possible .  Circumstances that may induce changes in HR, 
including environmental di stractions (e.g., television, radio, conversation), should be 
avoided during the pre- ECG resting period and during ECG recording.
Paper copi[INVESTIGATOR_737749] ’permanent study file at 
the site. The following should be recorded in the appropriate eCRF:  HR, QRS interval, 
PR duration, uncorrected QT interval, and QTcF based on the machine readings of the 
individual ECG tracings.  Any morphologic waveform changes or other ECG 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
51/Protocol WP40734 , Version 3.0abnormalities must be documented on the eCRF.  If considered appropriate by [CONTACT_429], ECGs may be analyzed retrospectively at a central laboratory.
If at a post -dose timepoint the mean QTcF is 500ms and/or [ADDRESS_1008051] for potential concurrent risk factors 
(e.g., electrolyte abnormalities, co -medications known to prolong the QT interval, severe 
bradycardia).
[IP_ADDRESS] Cardiodynamic ECG Evaluation
12-lead ECG s will berecorded continuously using a Holter device from at least [ADDRESS_1008052] be marked on the skin with permanent 
marker, to allow electrodes tobe positioned as consistently as possible throughout the 
study (Appendix 1and Appendix 2).
ECGs will be extracted from H olter devices at 3 time points pre-dose (-45, -30 and -15 
minutes) on Days 1, 2,14, and [ADDRESS_1008053]-dose on Days 1, 2, 14 and 15 (Appendix 1andAppendix 2).
The 24h Holter extraction time point for Days [ADDRESS_1008054] e collection.
During days with Holter ECG monitoring subjects (Appendix 1), willbe fed standardized 
low-salt meals .To reduce variability, Holter recording and supi[INVESTIGATOR_737750] W ork Instruction EDSEXE 009 W 131.
The 12-lead Holter will be supplied and supported by [CONTACT_150119].All ECG data will be
collected using a  [LOCATION_003]) M12R ECG continuous 
12-lead digital recorder. The continuous 12 -lead digital ECG data w ill be stored onto SD 
memory cards. ECGs to be used in the analyses will beselected by [CONTACT_094]-determined 
time points as defined in the SoA ( Appendix 1)and w ill be read centrally by [CONTACT_150119].
The following principals w ill be followed in ERT’s core laboratory:
ECG analysts w ill be blinded to the subject, visit and treatment allocation.

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
52/Protocol WP40734 , Version 3.0Baseline and on -treatment ECGs for a particular subject will be over-read on 
the same lead and w ill be analyzed by [CONTACT_336601].
The primary analysis lead is lead II. If lead II isnot analyzable , then primary 
lead of analysis will bechanged to another lead for the entire subject data 
set.
TQT Plus ECG Extraction Technique
Ten 14-second digital 12-lead ECG tracings will be extracted from the continuous Holter 
recordings using the ‘TQT Plus metho d’, a computer -assisted and statistical process 
utilized by [CONTACT_150119]. The method enables extraction of ECGs with the lowest HR variability 
and noise within the protocol -specified extraction time window (e.g., the HR and QT 
changes from beat-to-beat in the range of <10%). Ateach protocol -specified timepoint, 
10ECG replicates will be extracted from a 5 -minute “ECG window” (the last [ADDRESS_1008055] is maintained in a supi[INVESTIGATOR_737751]).
Expert -Precision QT Analysis
High-precision QT analysis will be performed on all analyzable (non-artifact) beats inthe 
10 ECG replicates. Statistical quality control procedures are used to review andassess 
all beats and identify “high” and “low” confidence beats using several crite ria,including:
QT or QTc values exceeding or below certain thresholds (biologically unlikely).
HR values exceeding or below certain thresholds (biologically unlikely).
Rapid changes in QT, QTc or HR from beat to beat.
Measurements of all primary ECG parameters (QT, QTc, HR) in all recorded beats ofall 
replicates that are deemed “high confidence” is performed using COMPAS software.   
All low confidence beats are reviewed manually and adjudicated using pass -failcriteria.
The final QC assessment is performed by a cardiologist. The beats found acceptable by  
[CONTACT_454565]. The median QT, QTc, andHR value from 
each extracted replicate is calculated, and then the mean of all available medians from a  
nominal timepoint is used as the subject’s reportable value at that timepoint.
Categorical T -wave morphology analysis and the measurement of PR and QRS intervals 
will be performed manually in 3 of the 10 ECG replicates at each timepoint. Each 
fiducial point (onset of P-wave, onset of Q-wave, offset of S-wave, and offset ofT-wave) 
is electronically marked.   
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
54/Protocol WP40734 , Version 3.0opulmonary valve regurgitation -absent or present . If present, used to 
estimate diastolic PAP
oRight ventricular wall thickness
oRight ventricular size; diameter
Doppler -echo parameters for evaluation of left heart:
oleft ventricular ejection fraction (LVEF)
oleft ventricular wall thickness
oRatio of transmitral Doppler early filling velocity (E) to tissue Do ppler early 
diastolic mitral annular velocity (E’)
oaortic valve insufficiency: if present, categorization asmild, moderate, 
severe
omitral valve regurgitation: if present, categorization as mild, moderate, 
severe per definition in theprocedure manual .
4.5.8 Ambulator y Blood Pressure Monitoring
Ambulatory Blood Pressure Monitoring (ABPM )will be performed on Day -[ADDRESS_1008056] udy the daytime period is defined as 
9:00 am to 9:00 pm and the nighttime period is defined as 1:00 am to 5:[ADDRESS_1008057].   
During the period of time that no assessments are planned on Day -1 and Day 12, i.e. ,
9:00pm to 1 :00am, subjects may remove the ABPM device to perform activities that 
would be hindered by [CONTACT_3433] e device , e.g.,to shower or change clothing .
Daytime period: Daytime is defined from 9 am to 9 pm for this study and blood pressure 
will be measured in 20- minute intervals during this period. Unusual or strenuous 
physical activities are not allowed during assessment periods . Subjects will be 
instructed not to sleep during this assessment period . The ABPM device maybe 
deactivated due to the need to perform other assessments including TT -Doppler 
echocardiograms.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
55/Protocol WP40734 , Version 3.0Nighttime period: Nighttime for this study is defined as from 1 am to 5:[ADDRESS_1008058] the bed.
Pulse rate will be recorded by [CONTACT_737776].
Further details of ABPM analysis will be provided in a separate manual.
4.5.9 Columb ia-Suicide Severity Rating Scale
The Columbia -Suicide Severity Rating Scale (C -SSRS) is a clinical tool used to assess 
the lifetime suicidality of a subject (C -SSRS lifetime version) as well as any new 
instances of suicidality (C -SSRS since last visit).
The structured interview prompts recollection of suicidal ideation, including the intensity 
of the ideation, behavior, and attempts with actual/potential lethality.
C-SSRS assessments will be completed by [CONTACT_737777], 
Day-2, Day16and at Follow -up visit s (Appendix 1).
4.5.10 Drug and Metabolite Concentration Measurements
For each Treatment Period plasma samples will be collected ,as described in
Appendix 1andAppendix 2,to determine concentrations of balovaptan and its 
metabolites M2 (as appropriate )and M3 utilizing a specific and validated liquid 
chromatography -tandem mass spectrometry (LC -MS/MS) method. Plasma 
concentrations of moxifloxacin will also be measured using a separate, specific and 
validated LC -MS/MS method.   
Moxifloxacin PK samples: wi ll only be analyzed if the moxifloxacin assay sensitivity test 
fails; in such case, moxifloxacin plasma levels matched to the QT data by [CONTACT_737778].   
4.5.11 Timing of Study  Assessments
If performed at the same timepoint, assessments should be prioritized as follows, while 
ensuring PK blood sampling is conducted at the scheduled time , when possible :  
12-lead ECGs
Vital signs measurements
PK blood sampling
Laboratory tests
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
56/Protocol WP40734 , Version 3.04.[ADDRESS_1008059] permanently discontinue study treatment if they experience any of the 
following:
Any medical condition that the Investigator , designee or Sponsor determines may 
jeopardize the subject ’s safety if he or she continues to receive study treatment .
Section 5.1.2 provides additional g uidance on the management of toxicities and of 
subjects who experience AEs within the outline of specific s toppi[INVESTIGATOR_004] .
Investigator , designee or Sponsor determines it is in the best interest of the subject
Pregnancy
The primary reason for study treatme nt discontinuation should be documented on the 
appropriate eCRF.  Subjects who discontinue study treatment may be replaced.
Subjects w ho terminate the study early while admitted to the CR Uwill have safety 
assessment sperform edas indicated for the Follow -up visit as described in SoA 
(Appendix 1)prior to discharge. In addition, subjects will be encouraged to return to the 
clinic for a Follow -up visit [ADDRESS_1008060] dose of study drug ( Appendix 1).
4.6.[ADDRESS_1008061] from the 
study at any time.  Reasons for withdrawal from the study may include, but are not 
limited to, the following :
Subject withdrawal of consent
Study termination or site closure
Subject non-compliance, defined as failure to comply with protocol requirements 
as determined by [CONTACT_737] , designee or Sponsor
Every effort should be made to obtain information on subjects who withdraw from the 
study.  The primary reason for withdrawal from the study should be docu mented on the 
appropriate eCRF. Subject request sto be withdrawn from the study must be 
documented in the source documents and signed by [CONTACT_737] (or designee).
Subjects who withdraw from the study may be replaced at the discretion of the 
Investi gator or Sponsor .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
57/Protocol WP40734 , Version [IP_ADDRESS] Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of AEs in this or other studies indicate s a potential health 
hazard to subjects
Subject enrollment is unsatisfactory
The Sponsor will notify the Investigator if the Sponsor decides to discontinue the study.
4.6.4 Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinic al Practice
No study activity (i.e., all subjects have completed the study and all obligations have 
been fulfilled)
5. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
Balovaptan is not approved in any country and clinical development is ongoing. The 
safety plan for subjects in this study is based on clinical experience with balovaptan in 
completed and ongoing studies. Potential safety risks for balovaptan are outlined below.
Please refer to the balovaptan ( RO5285119) Investigator’s Brochure for a complete 
summary of thesafety information available for the molecule.
Several measures will be taken to ensure the safety of subjects participating in this study .  
Eligibility criteria have been designed to exclude subjects at higher risk for toxicities .  
Subjects will undergo safety monitoring during the study, including assessment of the 
nature, frequency, and severity of adverse events .  In addition , guidelines for managing 
adverse events, including criteria for dosage modification and treatment interruption or 
discontinuation, are provided below .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
58/Protocol WP40734 , Version 3.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
59/Protocol WP40734 , Version 3.0 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS] Pulmonary  Blood Pressure
In animals as well as preparations of pulmonary vasculature, vasopressin has been 
shown to decrease pulmonary blood pressure and to relax arterial constriction through 
V1a receptors and in animals these changes were accompanied by [CONTACT_737768] .8,[ADDRESS_1008062] a change in pulmonary blood 
pressure representing half of 1 SD at of 0.05 and with a power of 80 %.
As an accompanied monitoring measure, the current database on systemic blood 
pressure monitoring is supplemented by [CONTACT_737779].
 
 
 
 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
60/Protocol WP40734 , Version 3.0 
  
  
 
 
[IP_ADDRESS] Orth ostasis
Inhibition of V1a receptors by [CONTACT_737780], particularly when moving rapi[INVESTIGATOR_269820] a supi[INVESTIGATOR_737752] 
a standing position.   
However, various biological systems besides the vasopressinergic system are involved 
in regulating blood pressure control and the relevance of isolated V1a receptor inhibition 
may be minor .  Safety pharmacology studies in dogs have not pointed to blood pressure 
lowering effect of balovaptan.
Orthostatic challenge testing was included in the Phase 2 study BP28420 and no 
imbalance was noted between placebo -and balovaptan -treated cohorts in the 
percentage of subjects (approximately 8%) showing relevant blood pressure changes.
No respective safety signals emerged from the MAD arm of study BP25694 nor from the 
proof -of-mechanism study (BP29412) when balovaptan doses of 52 mgqd were 
administered for several days .  However, no orthostatic challenge testing was included 
in these trials.
Given that a dose of either 10 mg or 50 mg qdbalovaptan is estimated to block the V1a 
receptor fully throughout the dosing interval, together with the clinical trial experience 
outlined above, the risk of balovaptan -related orthostatic impairment in this study is 
considered low.

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
61/Protocol WP40734 , Version 3.0As indicated above, this study monitors systemic blood pressure by [CONTACT_737781].
5.1.2 Management of Subjects Who Experience Adverse Ev ents
[IP_ADDRESS] Management Guidelines
In general, any emerging AEs must diligently be watched, treated as medically indicated 
according to common medical practice and documented in terms of onset -date, intensity, 
off-set date, and any measures taken in order t o treat the AE.
No specific treatment guidance to any potentially emerging AEs in balovaptan clinical 
trials exist and treatment should be according to the common medical practice for the 
given AE.
Temporary dosing interruptions must be discussed with the Sponsor’s Medical Monitor in 
the sense that temporary interruptions will have to be very limited in order to nor 
jeopardize the trial’s pharmacokinetic objectives .  Dose modifications because of an AE 
are not allowed in this study.   
 
 
 
 
 
  
 
  
 
  
 
 
  
 
 
 
 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
62/Protocol WP40734 , Version 3.0 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
63/Protocol WP40734 , Version 3.0 
  
 
 
[IP_ADDRESS] Changes in Pulmonary / Systemic Blood Pressure
While no relevant changes in pulmonary blood pressure are expected, should the 
TT-Doppler echocardiogram examination unexpectedly reveal such a change all 
available cardio -vascular and potential pulmonary data should be reviewed by 
[CONTACT_10670] (or designee )and cardiologist to assess the subj ect’s safety and to dec ide 
on
next actions which may include tr eatment interruption and / or perman ent treatment 
stop.  
An increase in mean pulmonary blood pressure of 25 mm/Hg will result in termination of 
study drug dosing and referral of the subject to a c ardiologist .  If logistically possible 
abnormal TT -Doppler echocardiogram sshould be repeated as soon as possible to 
confirm results.
The relevance of changes in the parameters obtained by [INVESTIGATOR_118059]-Doppler echo cardiogram
will be interpreted by [CONTACT_72324] .  A change in PAAT by 50% or more in a subject, is 
a safety signal that willresult in a discussion of discontinuing treatment for the affected
subject. 
Given current clinical experience for systemic blood pressure and HR, relevant changes 
in standard and ambulatory blood pressure monitoring (ABPM) monitoring are not 
expected .  However, repeated blood pressure changes exceeding the 
BPsystolic>160mmHg and/or BP diast olic>100mm Hg and that cannot be explained 
by [CONTACT_737782] .  For orthostatic events, please see also Section [IP_ADDRESS] .
[IP_ADDRESS] Management of Orthostatic Hypotension
Subjects with unexplained orthostatic reaction with syncope within the last 6 months ar e
excluded from this study.
Vital signs will be monitored frequently throughout the study as indicated in the SoA 
(Appendix 1).
Subjects will be instructed to avoid rapid body movements from supi[INVESTIGATOR_737753], and to inform the Investigator or designee as soon as possible should they 
experience dizziness, nausea, sweating, pale face, or even fainting with such body 
movements.

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
64/Protocol WP40734 , Version [IP_ADDRESS].[ADDRESS_1008063] (AESI) , performing protocol -specified safety laboratory 
assessments, measuring protocol -specified vital signs, and conducting other protocol -
specified tests that are deemed critical to the safety evaluation of the study. The 
schedule for conducting these activities is provided in the SoA ( Appendix 1).
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.[ADDRESS_1008064], regardless of causal attribution.  An AEcan therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an e xisting disease (a worsening in the 
character, frequency, or severity of a known condition) 
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
65/Protocol WP40734 , Version [IP_ADDRESS] Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the AEactuall y causes or leads to death)
Is life threatening (i.e., the AE, in the view of the Investigator or designee , places the 
subject at immediate risk of death)
oThis does not include any AEthat,had it occurred in a more severe form 
or was allowed to continue ,might have caused death.
Requires or prolongs subject hospi[INVESTIGATOR_059] (Section [IP_ADDRESS] )
Results in persistent or significant disability/incapacity (i.e., the AEresults in 
substantial disruption of the subject ’s ability to conduct normal life functions)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug s
Is a significant medical event in the Investigator or designee's judgment (e.g., may 
jeopardize the subject or may require medical/surgical intervention to prevent one of 
the outcomes listed above)
The terms "severe "and "serious "are notsynonymous.  Severity refers to the intensity of 
an adverse event ( e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [ NCI CTCAE ]; see 
Section 5.3.3 ); the event itself may be of relatively minor medical significance (such as 
severe headache without any further findings).
Severity and seriousness need to be independently assessed for each AErecorded on 
the eCRF.
Serious adverse events ar e required to be reported by [CONTACT_737783] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).
5.2.[ADDRESS_1008065] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_737] (or
designee )to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 for reporting instructions).  AESIs for this study are as follows :
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by [CONTACT_25742]'s 
Law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_5257] , as defined below
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
66/Protocol WP40734 , Version 3.0suspected from clinical symptoms or laboratory findings that indicate an 
infection in a subject exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
Clinically relevant decreases in ANC and for which no alternative explanatio n has 
been identified (i.e., the relationship to study drug is rated “yes”).
CPK values that exceed 10× ULN for several days without a trend of normalization 
or are associated with relevant dysfunction of kidneys, and if no alternative 
explanation exists.
Adverse events such as: 
oArrhythmia
oSyncope
oDyspnea
oPalpi[INVESTIGATOR_737754] .
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The Investigator is responsible for ensuring that all AEs are recorded on the Adverse 
Event eCRF and source for mand reported to the Sponsor in accordance with 
instructions provided in this Section and in Sections 5.4-5.6.
For each AErecorded on the Adverse Event eCRF and source form, the Investigator or 
designee will make an assessment of seriousness (see Section 5.2.2 ), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).  
5.3.[ADDRESS_1008066] ’s medical record and on the Adverse Event eCRF and source form .
After informed consent has been obtained but prior to initiation of study drug ,only SAEs
caused by a protocol -mandated intervention (e.g., invasive procedures such as biopsies, 
discontinuation of medications) should be reported (see Section 5.4.2 for instructions for 
reporting SAEs).
After initiation of study drug, all AEs will be reported until 21days after the last dose of 
study drug.
Instructions for reporting AEs that occur after the AEreporting period are provided in 
Section 5.6.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
67/Protocol WP40734 , Version [IP_ADDRESS] Eliciting A dverse Ev ent Information
A consiste nt methodology of non- directive questioning should be adopted for eliciting AE
information.  Examples of non -directive questions include the following:
"How have you felt since your last clinic visit? "
"Have you had any new or changed health problems since you were last here? "
5.3.[ADDRESS_1008067] normal daily activity
Severe Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may  also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 5.2.2 ).
5.3.[ADDRESS_1008068] , the circumstances 
surrounding the event, and an evaluation of any potential alternative causes to 
determine whether an AEis considered to be related to the study drug, indicating "yes"
or "no"accordingly.  The following guidance should be taken into co nsideration (see also 
Table 4 )
Temporal relationship of event onset to the initiation of study drug
Course of the event, with special consideration o f the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug ( asapplicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Presen ce of risk factors in the subject or use of concomitant medications known to 
increase the occurrence of the event
Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
68/Protocol WP40734 , Version 3.0Table 4Causal A ttribution Guidance
Is the AEsuspected to be caused by [CONTACT_25745], evidence, 
science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the AEand 
administration of the study drug, and the AEcannot be readily explained by [CONTACT_1560] 'sclinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the AE
follows a known pattern of response to the study drug; and/or the AEabates or reso lves 
upon discontinuation of the study drug or dose reduction and, if applicable, reappears 
upon re -challenge.
NO An AEwill be considered related, unless it fulfills the criteria specified below .  
Evidence exists that the AEhas an etiology other than the study drug (e.g., preexisting 
medical condition, underlying disease, intercurrent illness, or concomitant medication); 
and/or the AEhas no plausible temporal relationship to administration of the study drug 
(e.g., cancer diagnosed [ADDRESS_1008069] dose of study drug).
For subjects receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy f ollowing conclusion of the study and unblinding of 
study data .
5.3.[ADDRESS_1008070] medical terminology/concepts when 
recording AEs on the Adverse Event eCRF and source form .  Avoid colloquialisms and 
abbreviations.
Only one AEterm should be recorded in the event field on the Adverse Event eCRF and 
source form.
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
A diagnosis (if known) should be recorded on the Adverse Event eCRF and source form
rather than individual signs and symptoms (e.g., record only liver failure or hepatitis 
rather than jaundice, asterixis, and elev ated transaminases).  However, if a constellation 
of signs and/or symptoms cannot be medically characterized as a single diagnosis or 
syndrome at the time of reporting, each individual event should be recorded on the 
Adverse Event eCRF and source form .  Ifa diagnosis is subsequently established, all 
previously reported AEs based on signs and symptoms should be nullified and replaced 
by [CONTACT_371429], with a starting date that corresponds to 
the starting date of the first sympt om of the eventual diagnosis.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
69/Protocol WP40734 , Version [IP_ADDRESS].2 Adverse Events That A reSecondary  to Other Events
In general, AEs that are secondary to other events (e.g., cascade events or clinical 
sequelae) should be identified by [CONTACT_5252], with the exception of severe or 
serious secondary events.  A medically significant secondary AEthat is separated in 
time from the initiating event should be recorded as an independent event on the 
Adverse Event eCRF and source form .  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, bot h events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by a ninfection, both events should be reported 
separately on the eCRF.
All AEs should be recorded separately on the Adverse Event eCRF and source form if it 
is unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent AEis one that extends continuously, without resolution, between subject
evaluation timepoints.  Such events should only be recorded once on the Adverse Event 
eCRF and source form .  The initial severity (intensity or grade) of the event will be 
recorded at t he time the event is first reported.  If a persistent AEbecomes more severe, 
the most extreme severity should also be recorded on the Adverse Event eCRF and 
source form . If the event becomes serious, it should be reported to the Sponsor 
immediately (i.e. , no more than 24 hours after learning that the event became serious; 
see Section 5.4.2 for reporting instructions).  The Adverse Event eCRF and source form
should be updated by [CONTACT_25748] "non- serious" to "serious," providing the 
date that the event became serious, and completing all data fields related to SAEs.
A recurrent adverse event is one that resolves between subject evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF and source form .
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an AE.  A laboratory test r esult must be 
reported as an AEif it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
70/Protocol WP40734 , Version 3.0Results in a medical int ervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the Investigator or designee ’s judgment 
It is the Investigator or designee’s responsibility to review all laboratory findings.  Medical 
and scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an AE.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with chole stasis ), only the 
diagnosis (i.e., chole stasis ) should be recorded on the Adverse Event eCRF and source 
form.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF and source form , 
along with a descriptor indicating whether the test result is above or below the normal 
range (e.g., "elevated potassium, "as opposed to "abnormal potassium ").  If the 
laboratory abnormality can be characterized by a precise clinical term per standard 
definitions, the clinical term should be recorded as the AE.  For example, an elevated 
serum potassium level of 7.0 mEq/L shou ld be recorded as "hyperkalemia. "
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF and source form (see 
Section [IP_ADDRESS] for details on recording persistent AEs).
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an AE.  A vital sign result must be reported 
as an AEif it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the Investigator or designee ’s judgment 
It is the Investigator or designee’s responsibility to review all vital sign findings.  Medical 
and scientific judgment should be exercised in deciding whether an isolated vital sign 
abnor mality should be classified as an AE.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF and source form .
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
71/Protocol WP40734 , Version 3.0Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF and source form (see 
Section [IP_ADDRESS] for details on recording persistent AEs).
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by [CONTACT_25742]'s Law).  Therefore, Investigator or designees must report as an AEthe 
occurrence of either of the following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF and source form (see 
Section [IP_ADDRESS] ) and reported to the Sponsor immediately (i.e., no more than 24 hours 
after learning of the event), either as a SAE or an AESI (see Section 5.4.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adverse event reporting period (see 
Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and source form and immediately reported to the Sponsor (see 
Section 5.4.2 ).
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF and source form .  Generally, onl y one such event 
should be reported.  If the cause of death is unknown and cannot be ascertained at the 
time of reporting, "unexplained death "should be recorded on the Adverse Event eCRF 
and source form .  If the cause of death later becomes available (e.g., after autopsy), 
"unexplained death "should be replaced by [CONTACT_25749].   The term 
"sudden death" should not be used unless combined with the presumed cause of death 
(e.g., "sudden ca rdiac death").
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
[IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
72/Protocol WP40734 , Version 3.0recording such events on the Adverse Event eCRF and source f orm, it is important to 
convey the concept that the preexisting condition has changed by [CONTACT_13665] (e.g., "more frequent headaches ").
[IP_ADDRESS] Hospi[INVESTIGATOR_371415] (i.e., inpatien tadmission to a hospi[INVESTIGATOR_307]) or prolonged 
hospi[INVESTIGATOR_25676] a serious adverse event (per the 
definition of serious adverse event in Section 5.2.2 ), except as outlined below.
An event that leads to hospi[INVESTIGATOR_371416] a SAE:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402]
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
are met:
oThe hospi[INVESTIGATOR_737755] a SAE, but should be reported as an AEinstead:
Hospi[INVESTIGATOR_371418]
5.[ADDRESS_1008071] report such events to the Sponsor immediately; under no circumstances should 
reporting take place more than [ADDRESS_1008072] report to 
the Sponsor within 24 hours after learning of the event, regardless of relationship to 
study drug:
Serious adverse events (defined in Section 5.2.2 ; see Section 5.4.2 for details on 
reporting requirements )
Adverse events of special inte rest(defined in Section 5.2.3 ; see Section 5.4.2 for 
details on reporting requirements )
Pregnancies (see Section 5.4.3 for details on reporting requirements )
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
73/Protocol WP40734 , Version 3.0The Investigator or designee must report new significant follow -up information for these 
events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of 
the information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event’s out come, including recovery
Additional narrative information on the clinical course of the event
Investigator or designee s must also comply with local requirements for reporting serious 
adverse events to the local health authority and IRB/EC.
5.4.[ADDRESS_1008073] Information :
Medical Monitor : , M.D. (Primary)
Telephone No.:  
Mobile Telephone No.:
Medical Monitor: , M.D. (Secondary)
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study subjects , an Emergency Medical Call Center Help Desk 
will access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, 
provide medical translation service (if necessary), connect the Investigator or designee
with a [COMPANY_002] Medical Responsible (listed a bove and/or on the [COMPANY_002] Medical 
Emergency List), and track all calls.  The Emergency Medical Call Center Help Desk will 
be available [ADDRESS_1008074]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event (SAE) /AEof Special Interest Reportin g 
Form provided to Investigator or designee s should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by [CONTACT_737784] .

Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
74/Protocol WP40734 , Version [IP_ADDRESS].[ADDRESS_1008075] all 
case details that can be gathered immediately (i.e., within 24 hours after learning of the 
event) on the paper Clinical Trial Serious Adverse Event/Adverse Event of Special 
Interest Reporting Form provided to investigators and submitting the report, either by 
[CONTACT_294880].
Instructions for reporting SAEs that occur 21days after the last dose of study treatment 
are provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Subjects
Female subjects of childbearing potential will be instructed to immediately inform the 
Investigator or designee if they become pregnant during the study or within 90days after 
the last dose of study drug.  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24hours after learning of the pregnancy), either by [CONTACT_371431] .  Pregnancy 
should not be recorded on the Adverse Event eCRF and source form .  The Investigator
or designee should discontinue the study drug and counsel the subject , discussing the 
risks of the pregnancy and the possible effects on the fetus.  Monitoring of the subject
should continue until conclusion of the pregnancy.  Any SAE associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF and source form .  In addition, the Investigator or designee will 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available .  
[IP_ADDRESS] Pregnancies in Female Partners of Male Subjects
Male subjects will be instructed through the Informed Consent Form to i mmediately 
inform the Investigator or designee if their partner becomes pregnant during the study or 
within [ADDRESS_1008076] dose of study drug.  A paper Clinical Trial Pregnancy 
Reporting Form should be completed and submitted to the Sponsor or its designee 
immediately (i.e., no more than 24 hours after learning of the pregnancy), either by 
[CONTACT_371432].  Attempts should be made to collect and report details of the 
course and outcome of any pregnancy in the partner of a male subject exposed to study 
drug.  When permitted by [CONTACT_779], the pregnant partner would need to sign an 
Authorization for Use and Discl osure of Pregnancy Health Information to allow for 
follow -up on her pregnancy.  Ifthe authorization has been signed, the Investigator or 
designee should submit a Clinical Trial Pregnancy Reporting Form when updated 
information on the course and outcome of the pregnancy becomes available .  An 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
75/Protocol WP40734 , Version 3.0Investigator or designee who is contact[CONTACT_371433], to support an informed decision in coop eration with the treating physician and/or 
obstetrician.
[IP_ADDRESS] Abortions
Any abortion should be classified as a SAE (asthe Sponsor considers abortions to be 
medically significant), recorded on the Adverse Event eCRF and source form , and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 ).  
[IP_ADDRESS] Congenital A nomalies /Birth Defects
Any congenital anomaly/birth defect in a child born to a female subject exposed to study 
drug orthefemale partner of a male subject exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event form, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
5.4.4 Reporting Requirements for Cases of Accidental Overdose or 
Medication Error 
Accidental overdose and medication error (hereafter collectively referred to as "special 
situations"), a re defined as follows:
Accidental overdose:  accidental administration of adrug in aquantity that is higher 
than the assigned dose
Medication error:  accidental deviation in the administration of a drug 
In some cases, a medication error may be intercepted prior to administration of 
the drug.
Special situations are not in themselves adverse events but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 )  Special situations 
should be recorded as described below:
Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes.
Medication error that does not qualify as an overdose:  Enter the name [CONTACT_26865] a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_26669]) as the event term.  Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental 
overdose" as the event term.  Check the "Accidental overdose" and "Medication 
error" boxes.  Enter a description of the error in the additional case details.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
76/Protocol WP40734 , Version 3.0Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] "intercepted medication 
error" as the event ter m.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.
For study drug, each AEassociated with a special situation should be recorded 
separately on the Adverse Event eCRF and source form .  If the associated AEfulfills 
seriousness criteria, the event should be reported to th e Sponsor immediately 
(i.e., nomore than 24 hours after learning of the event; see Section 5.4.2 ).  Study drug 
AEs associated with special situations should be recorded as described below for each 
situation:
Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.
Medication error that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.
As an example, an accidental overdose that resulted in a headache would require the 
completion of two Adverse Event eCRF and source form , one to report the accidental 
overdose and one to report the headache.  The "Accidental overdose" and "Medication 
error" b oxes would need to be checked on both eCRF pages.
5.[ADDRESS_1008077] withdraws consent.  Every effort should be 
made to follow all SAEs considered to be related to study drug or trial -related procedures 
until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and source form and in the subject ’s medical record to 
facilitate source data verification.
All pregnancies reported during the stu dy should be followed until pregnancy outcome.
5.5.2 Sponsor Follow -Up
For SAEs , AESI , and pregnancies, the Sponsor or a designee may follow up by 
[CONTACT_756], fax, email, and/or a monitoring visit to obtain additional case details and 
outcome information (e.g., from hospi[INVESTIGATOR_8838], consultant reports, 
autopsy reports) in order to perform an independent medical assessment of the reported 
case.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
77/Protocol WP40734 , Version 3.05.6 ADVERSE EVENTS THAT OCCUR AFTER TH E ADVERSE 
EVENT REPORTING PERI OD
The Sponsor should be notified if the Investigator or designee becomes aware of any 
SAE that occurs after the end of the AEreporting period (defined as 21days after the 
last dose of study drug), if the event is believed to be related to prior study drug 
treatment.  These events should be reported through use of the Adverse Event eCRF 
and source form .  The Investigator or designee should report these events directly to the 
Sponsor or its designee, either by [CONTACT_200052]/Adverse Event of Special Interest Reporting Form using the 
fax number or email address provided to investigators.
5.[ADDRESS_1008078] 
experience to identify and expeditiously communicate possible new safety findings to 
Investigator (or designee ), IRBs, ECs, and applicable health authorities based on 
applicable legislation.
Independent from the causality assessment, the following SAEs and non- SAEs of 
special interest will be reported to the FDA on an expedited basis: death, arrhythmia, 
syncope, dyspnea, palpi[INVESTIGATOR_814], and chest pain.  
To determine reporting requirements for single AEcases, the Sponsor will assess the 
expectedness of these events using the following reference documen ts:
RO5285119 (Balovaptan) Investigator's Brochure
Moxifloxacin package insert as relevant in the [LOCATION_002] of America
The Sponsor will compare the s everity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the Investigator or designee 's assessment 
of causali ty and seriousness, with allowance for upgrading by [CONTACT_25753].
An aggregate report of any clinically relevant imbalances that do not favor the test 
product will be submitted to health authorities.
6. STATISTICA L CONSIDERA TIONS AND ANAL YSIS PLA N
A statistical analysis plan (SAP) will be generated by [CONTACT_737785].   
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
78/Protocol WP40734 , Version 3.06.1 DETERMINA TION OF SA MPLE SIZE
A sample size of 56subjects was chosen to obtain 4 8evaluable subjects.  Subjects are 
evaluable if ECGs are available for all three periods to allow (1) the derivation of the 
primary endpoint (i.e., change from baseline on Day14), and (2) the assessment of the 
effect of moxifloxacin.
Based on the calculat ion of the sample size for a TQT study (Zhang and Machado, 
2008)6, assuming a 1 -sided 5% significance level and a within -subject SD of 8 msfor 
ΔQTcF and a true mean difference of 3 ms in ΔQTcF between balovaptan and placebo, 
a sample size of 48 evaluable subjects who complete the study will provide a power of 
96.6% to demonstrate that the upper bound of all the 2 -sided 90% CIs on ΔΔQTcF will 
fall below [ADDRESS_1008079] -dose time points (0.5, 1.25, 2.5, 4, 8, 12 and 24 hours) .
Sample Size Determination for A ssay  Sensitivity :
Based on the calculation of the sample size for a TQT study from Zhang and Machado, 
[ZIP_CODE], as the test is performed at three time points separately (1.25, 2.5, and 4 hours) , a 
one-sided 5% significance level (with adjusted one -sided significance levels of 5%, 2.5% 
and 1.67%) is used along with a within -subject SD of 8 ms for ΔQTcF, a sample size of 
48 evaluable subjects who complete the study will provide a power of 99% to prove a 
mean difference of 5 ms in ΔQTcF between moxifloxacin and placebo (i.e., ΔΔQTcF) at 
1 ≥of the [ADDRESS_1008080] OF STUDY
The number of subjects who enroll, discontinue, or complete the study will be 
summarized.  Reasons for premature study withdrawal will be listed and summarized.  
Enrollment and major protocol deviations will be listed and evaluated for their potential 
effects on the interpretat ion of study results.
6.3 SUMMA RIES OF DEMOGRA PHIC AND BA SELINE 
CHA RACTERISTICS
Demographic and baseline characteristics (including age, sex) will be summarized using 
means, standard deviations, medians, and ranges for continuous variables and 
proportions for categorical variables, as appropriate.  Summaries will be presented 
overall and by [CONTACT_1570].
6.[ADDRESS_1008081] one dose of balovaptan, whether prematurely 
withdrawn from the study or not, will be included in the safety analysis. The safety data, 
including AEs, laboratory data, and vital signs, will be listed and summarized by [CONTACT_737786]. Reasons for withdrawal from study will be listed and summarized. 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
79/Protocol WP40734 , Version 3.0Concomitant medications, 12 -lead ECG data and clinically significant neurological 
examinations will be listed. Adverse events will be listed and summarized by [CONTACT_3148], 
body system and preferred term using the Medical Dictionary for Regulatory Activities 
(MedDRA). All verbatim AE terms will be mapped to MedDRA thesaurus terms, and AE 
severity will be graded according to Table 3.For laboratory and [ADDRESS_1008082] listings will be presented with abnormalities flagged.
For statistical analyses of results from TT -Doppler echocardiogram and ABPM please 
see Section s6.8and 6.9below.
6.6 PHA RMA COKINETIC A NALYSES
Subjects will be excluded f rom the PK analysis population if they significantly violate the
inclusion or exclusion criteria, deviate significantly from the protocol, or if data are
unavailable or incomplete. Excluded cases will be documented together with the reason
for exclusion. A ll decisions on exclusions from the analysis will be made prior to
database closure.
Pharmacokinetics are a secondary objective of this study. The specific objectives are
To investigate the pharmacokinetics of balovaptan, M2 (as appropriate) ,andM3.
To investigate the pharmacokinetics of moxifloxacin.
Individual plasma concentrations at each sampling timepoint for balovaptan, M2 (as 
appropriate) , M3, and moxifloxacin will be presented by [CONTACT_737787], including means, geometric means, ranges, standard deviations 
and coefficients of variation. Individual and mean concentration versus time will be 
plotted on linear and semi -logarithmic scales .
PK parameters will be estimated using standard non -compartm ental m ethods . All PK 
parameters for balovaptan, M2 (as appropriate) , and M3 will be presented by [CONTACT_737788], geometric means, 
medians, ranges, standard deviations and coefficients of variation.
The following balovaptan, M2 (as appropriate) , M3 PK parameters will be estimated:
Cmax: Day 1 and Day 14 for Treatment A and B
AUC0 -24h: Day 1 and Day 14 for Treatment A and B
Tmax: Day 1 and Day 14 for Treatment A and B
Ctrough: Day 11, 12, 13, 14 for Treatment A and B
Time to steady state for Treatment A and B
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
80/Protocol WP40734 , Version 3.0The following moxifloxacin PK parameters will be estimated:
Cmax, AUC0- 24h, and Tmax will be estimated on Days 2 (Treatment C) or 15
(Treatment D)
Additional PK analyses maybe be conducted as appropriate forbalovaptan, M2 (as 
appropriate) , M3 and moxifloxacin.
Subjects will be excluded from the PK analysis population if they significantly violate the 
inclusion or exclusion criteria, deviate significantly from the protocol, or if data are 
unavailable or incomp lete. Excluded cases will be documented together with the reason 
for exclusion. All decisions on exclusions from the analysis will be made prior to 
database closure.
6.7 CARDIODYNA MIC ECG EVALUTAION
The following ECG parameters will be measured and calculated: HR, PR, QT, QTcF, 
and QRS. T -wave morphology and U -wave presence will be assessed. 
The primary analysis will be based on by -time point analysis to evaluate the effect of 
balovaptan on the placebo -corrected change -from-baseline QTcF (ΔΔQTcF) at each 
post-dosing time point using the Intersection Union Test. The effect of balovaptan on 
placebo -corrected change- from-baseline in HR, PR, and QRS (ΔΔHR, ΔΔPR, and 
ΔΔQRS) will also be evaluated using the Intersection Union Test. In addition, the 
relationship between plasma concentrations of balovaptan and its metabolites (M2 [as 
appropriate ]and M3) and Δ ∆QTcF will be evaluated using a linear mixed-effects 
modeling approach. An analysis of categorical outliers will be performed for changes in 
HR, PR, QRS, QTcF, T -wave morphology and U -wave presence. Assay sensitivity will 
also be evaluated using by -time point analysis of the effect on Δ ∆QTcF of moxifloxacin 
using a simi lar model as for the primary analysis. 
6.7.[ADDRESS_1008083] 
one dose of the study medication (either balovaptan , moxifloxacin or matching placebo), 
whether prematurel y withdrawn from the study or not .
The PK population will include all subjects who receive at least [ADDRESS_1008084] 1 evaluable PK plasma concentration of balovaptan (and 
moxifloxacin, when applicable).
The QT/QTc popul ation will include all subjects in the Safety population with 
measurements at baseline as well as on -treatment with at least [ADDRESS_1008085] -dose time point 
with a valid ΔQTcF value. The QT/QTc population will be used for the by -time point and 
categorical analyses of cardiodynamic ECG parameters.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
81/Protocol WP40734 , Version 3.0The PK/QTc population will include all subjects who are in both the QT/QTc and PK 
populations with at least [ADDRESS_1008086] -dose PK and QTcF data from the same time point. 
The PK/QTc population will be used for the concentra tion-QTc analysis. PK/QTc 
population will be defined for balovaptan (and for moxifloxacin, when applicable).
6.7.[ADDRESS_1008087] of balovaptan versus placebo, baseline is defined as 
the average of the measured ECG intervals from the 3 pre -dose time points on Day1.
For the evaluation of assay sensitivity, the following baselines will be used:
Treatment C (Moxifloxacin / Placebo): For moxifloxacin dosed on Day2, baseline 
is defined as the average of the measured QTcF intervals from the 3 pre- dose 
time points on Day15. For placebo –correction in this group, placebo values will 
be derived from Day14, and baseline is defined as the average of the measured 
QTcF intervals from the 3 pre -dose time points on Day1.
Treatment D(Placebo / M oxifloxacin): For moxifloxacin dosed on Day15, 
baseline is defined as the average of the measured QTcF intervals from the 
3pre-dose time points on Day2. For placebo –correction in this group, placebo 
values will be derived from Day1, and baseline is def ined as the average of the 
measured QTcF intervals from the 3 pre -dose time points on Day14.
6.7.3 By-Time Point A nalysis
The statistical hypothesis to be tested for the primary assessment of QT prolongation for 
each dose of the balovaptan treatment is:
  : ∪   ( )−  ( ) ≥10,  =1,2,…,7
  : ∩   ( )−  ( ) <10,  =1,2,…,7
where   ( )and   ( )are the least squares ( LS)mean of ΔQTcFfor each dose of 
balovaptan and placebo at time point  on Day 14, respectively. 
The “by -time point” analysis for QTcF will be based on a linear mixed -effects model with 
change -from-baseline QTcF (ΔQTcF) as the dependent variable; gender ,period, 
sequence, time (categorical), treatment (balovaptan, and placebo), and time -by-
treatment i nteraction as fixed effects; and baseline QTcF as a covariate. An unstructured 
covariance matrix will be specified for the repeated measures at time points for subject 
within treatment period. If the model with an unstructured covariance matrix fails to 
converge, other covariance matrices such as compound symmetry and autoregressive 
will be considered. If the fixed effects for period and/or sequence should prove to be 
nonsignificant (i.e., if the p value > 0.1), these effects may be removed from the model 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
82/Protocol WP40734 , Version 3.0and the analysis will be repeated without those covariates. From this analysis, the LS 
mean and 2 -sided 90 % CI will be calculated for the contrast “balovaptan versus placebo” 
at each dose of balovaptan and each post -dose time point on Day [ADDRESS_1008088]-dose time points (0.5, 1.25, 2.5, 4, 8, 12, and 24 hours) on 
Day 14 (steady state) , balovaptan will be concluded not to have a significant eff ect on 
QT interval prolongation. 
6.7.[ADDRESS_1008089]-dosing (ΔHR, ΔPR, and ΔQRS). The same model will be used as described for 
QTcF in the by -time point analysis. Th e LS mean, SE, and 90% CI from the statistical 
modeling for both change -from-baseline and placebo -corrected change -from-baseline 
values will be listed in tables and graphically displayed.
6.7.[ADDRESS_1008090]-dose time points (1.25, 2.5, and 4 hours):
  : ∩   ( )−  ( ) ≤5,  =1,2,3
  : ∪   ( )−  ( ) >5,  =1,2,3
where   ( )and   ( )are the LS mean of ΔQTcFfor moxifloxacin and placebo at time 
point  , respectively.
The analysis to show assay sensitivity will be based on the change -from-baseline post -
dosing QTcF of moxifloxacin. The same model will be used as described for the primary 
analysis. For the 3 predefined time points (1.25, 2.5, and [ADDRESS_1008091] -dosing) , the 
contrast in treatment ΔΔQTc F =“moxifloxacin -placebo ”will be tested against the 1 -
sided null hypothesis ΔΔQTc F ≤5 ms on the 5% level. Multiplicity will be con trolled by 
[CONTACT_2329] a Hochberg procedure.10If after this procedure , the LS mean of ΔΔQTcFis 
significantly l arger than [ADDRESS_1008092] 1 time point of these 3 time points , assay 
sensitivity will be considered shown. In addition, 2 -sided 90% CIs will be obt ained for the 
contrast at all time points and used in the figures.
6.7.[ADDRESS_1008093] presence 
will be summarized in frequency tables with counts and percentages for both number of 
subjects and number of time points. For categorical outliers, the number (percentage ) of 
subjects as well as time points who had increases in absolute QTcF values > 450 and 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
83/Protocol WP40734 , Version 3.0≤480 ms, > 480 and ≤500 ms, or > 500 ms, and changes from pre- dose baseline of > 
30 and ≤60 ms, or > 60 ms; increase in PR from pre -dose baseline > 25% to a 
PR>200 ms ; increase in QRS from pre -dose baseline > 25% to a QRS > 120 ms; 
decrease in HR from pre -dose baseline > 25% to a HR < 50 bpm; and increase in HR 
from pre -dose baseline >25% to a HR >[ADDRESS_1008094] presence, the analyses will be focused on change from 
baseline (i.e., treatment -emergent changes).
6.7.7 Concentration- QTc Analy sis (Secondary  Analy sis)
The concentration -QTc analysis will be based on placebo -corrected change- from-
baseline QTcF (ΔΔQTcF). That is, for the placebo adjustment, the individual ΔQTcF for 
placebo calculated at a specific time point is subtracted from ΔQTcF for the same 
subject on balovaptan at the sa me time point to generate ΔΔQTcF. The relationship 
between plasma concentrations of balovaptan and its metabolites (M2 [as appropriate]
and M3) and ΔΔQTcF will be investigated by [CONTACT_119267] -effects modeling. 
A full model will include ΔΔQTcF as the depen dent variable, time -matched plasma 
concentrations of each analyte ( balovaptan, M2 [as appropriate] and M3 ) as the 
covariates, centered baseline QTcF as an additional covariate (i.e., baseline QTcF for 
individual subject at each post -dose time point subtrac ting the population mean baseline 
QTcF for all subjects), and subject as a random effect for both intercept and slopes, 
when applicable. Assay sensitivity may also be evaluated by a concentration -QTc 
analysis of the effect on ΔΔQTcF of moxifloxacin using a similar model as the above one.
The following model selection procedure among the full model and reduced models from 
possible first order combinations (without quadratic and interaction terms ) among the 
three analytes (including models with only one analy te and with any two analytes) will be 
conducted by [CONTACT_737789] (AIC) and the t -value for the intercept 
estimator.5The selection will start from the full model and remove the analyte with the 
least significant slope from the model u ntil only one analyte is left to evaluate the most 
appropriate model(s). Note that a significant intercept is not biologically plausible and 
therefore indicates model misfit. The selection of the final models will be performed 
among those models with an absolute t -value for the intercept estimate <1.95. Nonlinear 
models (Emax model) will be included in this set only if the test for linearity indicates 
non-linearity. Among these models, the model with the smallest AIC will be selected as 
primary. If non e of the models qualify according to the condition on the t -value for the 
intercept estimator, non -linear models will be considered.
If the primary model selected from model comparison includes two or more analytes, 
then all analytes will be used to predict QTc Feffect. The geometric mean of the 
individual C max values of each analyte for subjects at each of balovaptan dose groups 
will be determined together with the geometric mean concentrations of the other two 
analytes at the T max of this analyte. The predicted effect and its 2 -sided 90% CI for 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
84/Protocol WP40734 , Version 3.0ΔΔQTcF interval at these pairs of concentrations will be obtained for the models with two 
or three analytes.
The plot of the observed median- quantile balovaptan (M2 or M3) concentrations and 
associated mean ΔΔQTcF interval (90% CI) together with the regression line presenting 
the predicted ΔΔQTcF interval (90% CI) (Tornoe et al, 2011) will be used to evaluate the 
adequacy of the model fit of the primary model to the assumption of linearity and the 
impact on q uantifying the concentration -QTcFrelationship. For models with two or three 
analytes, the analyte not presented at the x -axis will be set to the arithmetic mean 
concentration across all subjects under this analyte at the T max of the analyte presented 
at the x -axis. For evaluation of the HRcorrected QT interval, scatter and quantile plots 
of QTcF and HR intervals by [CONTACT_737790] 
(90% CI) will be also given, respectively. Additional exploratory analyses (vi a graphical 
displays and/or model fitting) will include accounting for a delayed effect (hysteresis) and 
the justification for the choice of PD model (linear versus nonlinear) as follows.
6.7.[ADDRESS_1008095] squares (LS) 
mean difference between ΔQTcF under balovaptan and under placebo (ΔΔQTcF) for 
each post -dose timepoint and the mean concentrations of balovaptan, M2 and M3 at the 
same timepoints. In addition, hysteresis plo ts will be given for mean ΔΔQTcF and each 
of the mean concentrations of balovaptan, M2, and M3. If a QT effect ( ∆∆QTcF) > 10 ms
cannot be excluded from the by -timepoint analysis and if a delay between peak ∆∆QTcF 
and peak plasma concentration in any of the se three plots (ΔΔQTcF versus balovaptan, 
ΔΔQTcF versus M2, and ΔΔQTcF versus M3) of more than [ADDRESS_1008096] residuals versus concentration and 
versus fitted values and versus centered baseline QTcF will be produced. The scatter 
plots of standardized residuals versus concentration and versus centered baseline QTcF 
by [CONTACT_737791] (i.e., locally weighted scatter plot smoo thing as described by [CONTACT_737792] 
1979) will also be produced with optimal smoothing parameters selected by [CONTACT_336608] a correction .12In addition, a model with the original terms, and 
quadratic and interaction terms of the concentrations of balovaptan, M2 (as appropriate)
and M3 will be fitted, and the quadratic and interaction terms will be tested on the 
2-sided 5% level. If there is an indication that a linear model is inappropriate, additional 
models will be fitted, in p articular a n Emax model .The additional non -linear models 
(Emax) will be added to the candidate set for the primary model if the t -value for the 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
85/Protocol WP40734 , Version 3.0intercept estimate is < 1.95 (see above). The concentration- QTc analysis will then be 
repeated for the model found to best accommodate the nonlinearity detected.
6.[ADDRESS_1008097] -hoc.
6.9 BLOOD PRESSURE A ND H EART RA TE MONITORING
Blood pressure and HRwill be analyzed combined and sepa rated for 2 time periods, 
daytime and nighttime . For this study, daytime is defined as 9:00 am to 9:00 pm and 
nighttime is defined as 1:00am to 5:30 am. Summary statistics will be provided for 
systolic and diastolic blood pressure as well as for HRand compared between 
treatments.
Systolic and diastolic blood pressure will be summarized combined and separate across 
daytime and nighttime assessment periods as mean of all valid measurements with only 
implausible measurement results being considered invalid and removed from analysis. 
Categorical analyses for the mean blood pressure of respective period according to the 
following categories:
Table 5 Threshold for Hy pertension Diagnosis Based on A mbulator y 
Blood Pressure Monitorin g
Assessments Time Period Ambulatory Blood Pressure
Daytime mean ≥ 130/85 mm Hg
Night time mean ≥ 120/70 mm Hg
In addition, categorical analyses for systolic and diastolic blood pressure as well for 
heart rate will be performed (details will be outlined in the SAP).
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
86/Protocol WP40734 , Version 3.0The categorical analyses include a comparison of thenumber of outliers by [CONTACT_737793]: A value for a subject is considered to be an outlier at a non-
treatment time point if the mean daily systolic BP at the follow -up time point was 
≥180mmHg and it was at least a 20 mmHg increase from the subjec t’s baseline mean 
daily systolic BP.  A value for a subject is considered to be an outlier at a n on-treatment 
time point if the mean daily diastolic BP at the follow -up time p oint was ≥105mmHg 
and it was at least a [ADDRESS_1008098] 's baseline mean daily diastolic 
BP.
Additional exploratory analyses may be made post -hoc.
7. DATA COLLECTION A ND M ANAG EMENT
7.[ADDRESS_1008099] data clarification from the sites.
PRA will produce a Data Quality Plan that describes the quality checking to be 
performed on the data. Central laboratory data will be sent directly to PRA using PRA’s 
standard procedures to handle and process the electronic transfer of these data. CRFs 
and correction documentation will be maintained in the EDC system’s audit trail.  System
backups for data stored by [CONTACT_398150] ’s standard procedures.
The Sponsor will perform over sight of the data management of this study, including 
approval of the PRA’s data management plans and specifications. Data will be 
periodically transferred electronically from PRA to the Sponsor, and the Sponsor’s
standard procedures will be used to handle and process the electronic transfer of these 
data. 
Electronic CRFs and correction documentation will be maintained in the EDC system’s 
audit trail. System backups for data stored at the CRO and records retention for the 
study data will be consistent wi th the CRO’s standard procedures. eCRFs and 
correction documentation will be maintained in the EDC system’s audit trail.  System 
backups for data stored at the CRO and records retention for the study data will be 
consistent with the CRO’s standard procedu res. 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
87/Protocol WP40734 , Version 3.07.[ADDRESS_1008100] disc is required.
7.3 SOURCE DA TA DOCUMENT ATION
Study monitors will p erform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and verifiable from source documents. 
Source documents (paper or elec tronic) are those in which subject data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subject -reported outcomes, 
evaluation checklists, phar macy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_26671], microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
subject files, and re cords kept at pharmacies, laboratories, and medico -technical 
departments involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.5.
To facilitate source data verifica tionand review , the Investigator (or designee s)and 
institutions must provide the Sponsor direct access to applicable source documents and 
reports for trial -related monitoring, Sponsor audits, and IRB/EC review.  The study site 
must also allow inspection by [CONTACT_25756].
7.4 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
88/Protocol WP40734 , Version 3.0as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data. If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name [CONTACT_33508], and date of the change.
7.[ADDRESS_1008101] reported outcome (PRO )data 
(ifapplicable), Informed Consent Forms, laboratory test results, and medication 
inventory records, must be retained by [CONTACT_079] [INVESTIGATOR_25653] [ADDRESS_1008102] to local regulations.  
No records may be disposed of without the written approval of the Sponsor .  Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another loca tion.
8. ETHICA L CONSIDERA TION S
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the co untry in which the research is conducted, whichever affords the 
greater protection to the individual.15  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporti ng).  Studies conducted in the [LOCATION_002] or under a U.S. 
Investigational New Drug (IND ) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.16,17  Studies conducted in the European Union
or European Economic Area will comply with the E.U. Clinical Trial Directive 
(2001/20/EC).
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’s Informed Assent Form or Mobile Nursing Informed Consent 
Form, if applicable) will be provided to each site.  If applicable, it will be provided in a 
certified translation of the local language.  The Sponsor or its designee must review and 
approve any proposed deviations from the Sponsor's sample Informed Consent Forms 
or any alternate consent forms proposed by [CONTACT_779] (collectively, the "Consent Forms") 
before IRB/EC submission.  The final IRB/EC approved Consent Forms must be 
provided to the Sponsor for health authority submission purposes accor ding to local 
requirements.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
89/Protocol WP40734 , Version 3.0If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The Investigator or authorized designee will explain to each subject the 
objectives, methods, and potential risks associated w ith each optional procedure.  
Subjects will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature [CONTACT_33509] a subjec t's agreement to participate in optional procedures.  Subjects who 
decline to participate will not provide a separate signature.
The Consent Forms must be signed and dated by [CONTACT_29159] ’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each subject shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study proce dures 
or when new information becomes available that may affect the willingness of the 
subject to participate.  The final revised IRB/EC -approved Consent Forms must be 
provided to the Sponsor for health authority submission purposes.
Subjects must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the ca se history or clinical records for each subject shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the subject or the subject’ s
legally authorized representative.  All signed and dated Consent Forms must remain in 
each subject’ sstudy file or in the site file and must be available for verification by [CONTACT_33483].
8.[ADDRESS_1008103] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
Inaddition, any subject recruitment materials must be approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  Investigator or designee s are also 
responsible for promptly informing the IRB/EC of any protoc ol amendments (see 
Section 9.6).
In addition to the requirements for reporti ng all adverse events to the Sponsor, 
Investigator or designee s must comply with requirements for reporting serious adverse 
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
90/Protocol WP40734 , Version 3.0events to the local health authority and IRB/EC.  Investigator or designees may receive 
written IND safety reports or other safety -related communications from the Sponsor .  
Investigator or designee s are responsible for ensuring that such reports are reviewed 
and processed in accordance with health authority requirements and the policies and 
procedures established by [CONTACT_11577]/ EC and archived in the site’s study file. 
8.[ADDRESS_1008104] parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosu re of personal health information) signed by [CONTACT_289336] t, unless permitted or required by [CONTACT_2371].
Medical information may be given to a subjec t's personal physician or other appropriate 
medical personnel responsible for the subject 's welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
subjects unless required by [CONTACT_2371].  The aggregate results of any conducted res earch will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.5).
Data generated by [CONTACT_25757], Sp onsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
Study data, which may include data on genomic variants, [applicable if the study is 
collecting mandatory (i.e., not requiring separate patient consent) samples for analysis of 
genomic variants]} may be submitted to government or other health research databases 
or shared with researchers, government agencies, companies, or other groups that are 
not participating in this study.  These data may be combined with or linked to other data 
and used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease.  In 
addition, redacted Clinical Study Reports and other summar y reports will be provided 
upon request (see Section 9.5).
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurat e 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section 3.2).
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
91/Protocol WP40734 , Version 3.09. STUDY DOCUMENTATION, MONITORING, A ND 
ADMINISTRA TION
9.[ADDRESS_1008105] of 
the study to be fully documented, including, but not limited to ,the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC approval.  In 
addition, at the end of the study, the Investigator will receive the subject data, including
an audit trail containing a complete record of all changes to data.
9.[ADDRESS_1008106]
safety and data integrity to the Sponsor and to the IRB/EC in accordance with 
established IRB/EC policies and procedures.  The Sponsor will review all protocol 
deviations and asses s whether any represent a serious breach of Good Clinical Practice 
guidelines and require reporting to health authorities.  As per the Sponsor's standard 
operating procedures, prospective requests to deviate from the protocol, including 
requests to waive p rotocol eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], subjects 'medical records, and eCRFs.  The Investigator or 
designee will permit natio nal and local health authorities; Sponsor monitors, 
representatives, and collaborators; and the IRBs/ECs to inspect facilities and records 
relevant to this study.
9.4 ADMINISTRA TIVE STRUC TURE
This trial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Central facilities will be used for certain study assessments throughout the study (e.g., 
specified laboratory tests, biomarker and PK analyses), as spe cified in Section 4.5.  
Accredited local laboratories will be used for routine monitoring; local laboratory ranges 
will be collected.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
92/Protocol WP40734 , Version 3.09.5 PUBLICA TION O F DATA  AND PROTECTIO N OF TRA DE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, both at scientific 
congresses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.   For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_s tudy_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in subjects involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within [ADDRESS_1008107] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trial s only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].
Authorship will be determined by [CONTACT_679825].  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_371438].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor , except where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol am endments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to subjects or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
93/Protocol WP40734 , Version 3.010. REFERENCES
1.Shin JY, Roughead EE, Park BJ, et al. Cardiovascular safety of methylphenidate 
among children and young people with attention -deficit/hyperactivity disorder 
(ADHD):nationwide self -controlled case series study. BMJ. 2016;353:i2550.
2.Sherazi S, DiSalle M, Daubert JP, Shah AH. Moxifloxacin- induced torsades de 
pointes. Cardiol J. 2008;15(1):71 -3
3.US Food and Drug Administration. Guidance for industry: E14 clinical evaluation 
of QT/QTc interval prolongation and proarrhythmic potential for non -
antiarrhythmic drugs . Food and Drug Administration. 2005 .
4.Darpo B., Benson C, Dota C, et al. Results from the IQ -CSRC prospective study 
support replacement of the thorough QT study by [CONTACT_119309]. Clin. Pharmacol Ther. 2015; 97(4): 326 -35.
5.Ferber G, Zhou M,Darpo B. Detection of QTc effects in small studies --
implications for replacing the thorough QT study. Annals of Noninvasive 
Electrocardio. 2015;20(4):368 -77.
6.Zhang J .Machado G. Statistical issues including design and sample size 
calculation in thorough QT/QTc Studies . J Biopharm Stat .2008 ;18:(3):451—67.
7.Sherazi S, DiSalle M, Daubert JP, Shah AH. Moxifloxacin -induced torsades de
pointes. Cardiol J. 2008;15(1):71 -3.
8.Eichinger, M R, Walker BR. "Enhanced pulmonary arterial dilation to arginine 
vasopressin in chronically hypoxic rats." Am J Physiol . 1994;267(6 Pt 2)
H2413 -19.
9.Walker BR, Haynes Jr JO, W ang HL, Voelkel NF. Vasopressin -induced 
pulmonary vasodilation in rats. Am J of Physiol .1989 ;257(2):H415 -22.
10.Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika . 1988; 75, 800 –2.
11.Cleveland W S. Robust Locally W eighted Regression and Smoothing Scatter 
Plots. J Amer Statist Assoc. 1979;74(368):829 -36.
12.Hurvich CM, Simonoff JS, Tsai CL. Smoothing parameter selection in 
nonparametric regression using an improved Akaike information criterion.  J Roy 
StatistSoc Ser B. 1998;60(2):271 -93.
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
94/Protocol WP40734 , Version 3.013.Tornøe C W, Garnett CE, W ang Y, Florian J, Li M, Gobburu JV.  Creation of a 
knowledge management system for QT analyses. J Clin Pharmacol. 2011; 51 (7): 
1035 -42.
14.Al-Mosalem OA, El -Ansary A, Attas O, Al -Ayadhi L. Metabolic biomarkers related 
to energy metabolism in Saudi autistic children. Clinical biochemistry. 2009 Jul 
1;42(10 -11):949- 57.
15.World Medical Association. World Medical Association Declaration of Helsinki: 
ethical principles for medical research involving human subjects. Jama. 2013 
Nov 27;310(20):2191.
16.International Conference on Harmonisation of Technical Requirements for 
Registration of Pharm aceuticals for Human Use. ICH Harmonised Tripartite 
Guideline, E3: Structure and Content of Clinical Study Reports 
(CPMP/ICH/137/95), November 1995
17.International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite
Guideline, E2A: Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting, Note for Guidance on Clinical Safety Data Management, 
June 1995
Balovaptan —F. Hoffmann -La [COMPANY_002] Ltd
95/Protocol WP40734, Version 3.0 Appendix 1
Schedule of A ctivities
Assessments Screening Nominal Study  Day  for Each Treatment PeriodFollo w
-upa
Days 
-28 to -3Day 
-2Day 
-1Day 
1Day 
2Day 
3Day 
4Day 
5Day 
6Day 
7Day 
8Day 
9Day 
10Day 
11Day 
12Day 
13Day 
14Day 
15Day 
16
Written informed 
consent
Inclusion and exclusion 
criteria
Randomization 
Medical history 
Conmeds review  
Physical examination   
Height and weightb 
Preand post -dose 
fastingc    
Standardized low salt 
mealsd       
Vital signse           
TT-Doppler 
echocardiogram 
ABPM  
Laboratory safety testsf     
12-lead safety ECGg           
12-lead ECG Holter 
monitoringh    
Administration of 
investigational 
medicinal product              
Drugs of abuse screeni 
Orthostatic challenge 
testing 
Urine alcohol screenj 
Pregnancy testk 
Follicle stimulating 
hormonel 
Appendix 1
Schedule of A ctivities (cont.)
Balovaptan —F. Hoffmann- La [COMPANY_002] Ltd
96/Protocol WP40734 , Version 3.0a.Follow -up visit should occur between [ADDRESS_1008108] 10 minutes. 
(See Appendix 2for details for vital signs taken on d ays with study drug treatment will be administered [Days 1, 3, 6, 9,11,13,14, and 15 ])
f.Includes hematology, biochemistry, urinalysis, coagulation and serology (coagulation and serology will be performed only during S creening)
g.Safety ECG assessments: Triplicate ECG measurements at Screening andDay -2. Single ECG measurements at Day 1, Day 3, Day 6, Day 9, Day 11, Day 13, Day 14, Day [ADDRESS_1008109] 10 minutes
h.ECG Holter monitoring assessments will be recorded on study Days 1, 2, 14 and 15 (See Appendix 2for additional details). 
All ECG measurements are to be recorded while the subject remainssupi[INVESTIGATOR_1919] 1 5minutes .
ECGs will be extracted from Holters at 3 time points pre -dose ( -45, -30 and -15 minutes) and7 time points post-dose (0.5, 1.0, 2.5, 4, 8, [ADDRESS_1008110] -dose ).The 24-hour post-
dose extraction time point for Days [ADDRESS_1008111] -dose. W henever ECG extraction and PK sample timepoints are close together the ECG extraction will be performed prior to PK sample collection .
i.Drugs of abuse: amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_371413], cocaine, opi[INVESTIGATOR_858], methamphetamines, methadone and 3 ,4Methylenedioxymethamphetamine (MDMA), 
will be measured in urine atScreening and Day 2. Additional testing may be performed during the study , at the discretion of the Investigator or designee ,to confirm subject 
compliance.
j.Planned at Screening and Day -2,further testing may be performed during the study , at the discretion of the Investigator or designee ,to confirm subject compliance.
k.Serum pregnancy test
l.Assessed for all females.
m.See Appendix 2for PK sampling details
n.Blood samples for the assessment of early markers of cardiac damage: troponin I, cTnT and NT-proBNP ,will be taken and stored but not analyzed unless requested for a specific 
subject .
o.Optional blood sample for Clinical Genotypi[INVESTIGATOR_737756]. N.B. one sample only to be collected and only if consented for this sample
PRIORITY OF ASSESSMENTS :where appropriate and feas ble: ECG > Vital Signs > Blood Sampling > Lab Safety TestsBlood sampling for 
balovaptan PKm     
Blood sampling for 
moxi floxacin PKm  
Cardiac biomarkersn 
C-SSRS    
Adverse Events                   
Blood sampling for 
Clinical Genotypi[INVESTIGATOR_737757] —F. Hoffmann -La [COMPANY_002] Ltd
97/Protocol WP40734, Version 3.[ADDRESS_1008112] -dose
Pre-dose 0.5 1.0 2.5 3 4 6 8 12 24a
12-lead ECG Holter 
monitoringb       
Vital Signs   
Blood collection for 
pharmacokineticsc        
a.On days when consecutive 24hourand pre-dose assessments are being done, only one 
assessment needs to be done prior to dose. This includes Holter extractions where the 24-hour
post-dose extraction time point for Days [ADDRESS_1008113] on 
study Days1, and 14for balovaptan andDays 2 and15for moxifloxacin . On other study days 
with PK sampling and study drug dosing (Day s 11, 12, 13) a single PK sample will be drawn 
prior to dosing with study drugs. This pre-dose sample also serves as the 24h post-dose 
samplefor the previous days dosing .A balovaptan PK sample will be taken on Day [ADDRESS_1008114]- dose sample .